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Chapter One 
 
Introduction 
 
A. Parkinson’s Disease. 
Human history is accompanied by people combating disease. However, developments in the 
biological sciences, particularly recent breakthroughs in molecular and genetic biology, have led to 
significant advances in knowledge concerning the human body and its diseases.1,2 Nevertheless, there 
are numerous diseases, notably those afflicting the brain and central nervous system, about which their 
mechanism or origin are largely unknown, and for which there are no cures. Parkinson’s disease (PD) 
is one such disorder.3  
PD is a degenerative brain disorder that has been known from ancient times.  Nonetheless, it 
was first formally documented in 1817 by the British physician James Parkinson in his book: An 
Essay on the Shaking Palsy in which he described PD as having the following physical manifestations: 
tremor, muscular rigidity, bradykinesia and simian posture.4 Currently, PD affects millions of people 
worldwide afflicting about 1% of people older than 60 years of age.5  
It took more than another century for biomedical scientists to obtain any insights into the 
pathogenesis of PD. In the 1950s, a critical breakthrough was obtained by a Swedish scientist, Arvid 
Carlsson, who discovered key biochemical change in the brains of PD patients. In his discovery, 
Carlsson noted that dopamine, which prior to that time was believed to be of importance solely as the 
precursor of norepinephrine, was in fact itself probably a key neurotransmitter in the nigrostriatal 
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pathway. Furthermore, Carlsson also discovered that a profound decrease of dopamine content in the 
substantia nigra pars compacta (SNpc) was characteristic in the brains of PD patients.6 Carlsson’s 
contributions led to the award of the 2000 Nobel Price in Physiology or Medicine. They also led to the 
discovery and use of 3,4-dihydroxy-L-phenylalanine (L-DOPA, the precursor of dopamine) as the 
only truly effective PD therapy.7,8 
Despite extensive investigations over the past fifty years or more, the cause(s) of  PD remain 
unknown and hence most forms of the disorder are referred to as idiopathic (i.e., of no known cause). 
However, a small number of PD cases have been linked to exposure to certain toxic substances, drugs, 
genetic mutations, and head trauma.3,9-16 Aging is considered to be the most robust risk factor for 
PD.17 However, the reasons for the more rapid dropout of dopaminergic neurons in the SNpc of PD 
patients than for age-matched controls remains a mystery.18 
There is no definitive diagnosis for PD; its earliest symptoms are non-specific including 
weakness, tiredness, and fatigue. When the characteristic symptoms of PD become clearly evident 
approximately 70-80% of striatal dopamine (DA) has been irreversibly lost.19  
Neurosurgery was employed to treat the symptoms PD patients for many decades before 
L-DOPA therapy was introduced in the1960s but has now been nearly totally abandoned because of 
unexpected and, often, deadly side-effects.20,21 While still in its infancy, stem cell implantation has 
attracted considerable attention, although this enthusiasm has been severely dampened by 
unsuccessful attempts at implantation of DA neurons from fetal tisue.22-24,25   
For many decades, L-DOPA was considered the only effective, although only symptomatic, 
therapy for PD. Administration of L-DOPA increases DA levels in the patient’s brain thus relieving the 
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symptom of PD. However, L-DOPA does not halt further deterioration of nigrostriatal dopaminergic 
neurons. Furthermore, after long term use the therapeutic effects of L-DOPA decline and debilitating 
side-effects develop such as aberrant movement, nausea, blood pressure changes, and psychiatric 
complications. These side effects eventually make L-DOPA therapy of limited value.7,8,20,26  
Figure 1-1 outlines the biosynthetic pathway for catecholamines. DA, norepinephrine (NE), 
and epinephrine (EPI) are all catecholaminergic neurotransmitters and the DA and to a lesser extent 
NE pathways are affected in PD. In this dissertation research, all of these neurotransmitters were 
targeted for in vivo monitoring by the system developed. 
 
B. An Animal Modal of PD 
A series of tragic events that occurred in late 1970s and early 1980s led to, arguably, the best 
animal model of PD.27 It all began with a 23-year old Maryland chemistry graduate student, Barry 
Kidston, who developed symptoms of advanced PD a few days after injecting himself with a 
home-synthesized synthetic heroin. Kidston had been attempting to synthesize MPPP 
(1-methyl-4-phenyl-4-propionoxypiperidine). However the synthetic route he employed accidentally 
created an unexpected byproduct – 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This event 
attracted little notice at that time. However, in July 1982 there was a further outbreak when six young 
addicts also simultaneously developed PD in Santa Clara County, California. MPTP was readily 
identified as the probable culprit for this outbreak of PD. 
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Figure 1- 1. Biosynthetic pathway for catecholamines. 
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Figrure 1- 2. Chemical structures of MPPP and MPTP. 
 
The mechanism of action of MPTP is widely believed to hold the key to an understanding and 
treatment of PD.28,29 Thus, research has shown that MPTP evokes PD symptoms when administered to 
non-human primates and rodents such as mice. However, rats seem have a particularly strong 
resistance to MPTP toxicity apparently related the difficulty of systemically administered MPTP 
crossing the blood-brain barrier.30,31 However, direct perfusion of MPTP or its active metabolite MPP+ 
into the striatum or SNpc of rats causes the same biochemical, pathological and immunohistochemical 
changes as other animal models systemically administered MPTP.32,33  
Figure 1-3 shows the putative metabolism of MPTP. The upper part of Figure 1-3 shows the 
metabolism of MPTP to 4-phenyl-1,2,3,6-tetrahydropyridine (PTP) catalyzed by cytochrome P-450 
oxidase and to MPTP-N-oxide via flavin monooxygenase. These two pathways, which occur primarily 
in the liver, are considered to be detoxication pathways.  The lower pathway is believed to be the 
metabolic activation of MPTP to its highly toxic metabolite 1-methyl-4-phenylpyridinium (MPP+). 
The first step in this pathway is the transformation (oxidation) of MPTP to 1-methyl-4-phenyl-2,3- 
dihydropyridinium (MPDP+) catalyzed by monoamine oxidase B (MAO-B), a process that has 
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considerable experimental support. However, the biochemical details of the oxidation of MPDP+ to 
MPP+ is still the subject of investigation.34-36 As part of the dissertation research, these molecules were 
targeted for in vivo monitoring. 
 
 
Figrure 1- 3. Putative metabolism of MPTP. 
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C. Systems Biology, Metabolomics and HPLC-MS Methods – the 
Future for PD. 
 
 
Figrure 1- 4 Traditional view (A) and –omics view (B) of biology systems 
 
Currently, many scientists believe systems biology holds the key to understanding and finding 
cures for disorders such as PD.2,37-43 This is because systems biology aims to integrate genomic, 
proteomic, transcriptomic, and metabolomic information to give a more complete picture of living 
organisms.44 Figure 1-4 compares the traditional and current ‘–omics’ view of biological systems.  
Systems biology has existed as a concept for at least fifity years. However, it was the critical 
development of new experimental devices and novel analytical methods that made it a realistic 
concept.40, 45-47  Although completion of the human genome project greatly boosted systems biology, 
it is still considered to be in its infancy mainly because the crucial techniques for proteomics and 
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metabolomics still need to be fully developed and implemented.48,49 These future techniques have to 
be as effective as the polymerase chain reaction (PCR) and high-throughput fully automated gene 
sequencing machines have been to the development of genomics.  
Metabolomics, which occupies the end position of the -omics cascade, measures all of the 
small molecules (metabolome) in an organism.44 The metabolome is the end product of cellular 
functions and its study holds the key to an understanding of fundamental questions bearing on the 
activity of proteins,  physiological mechanisms for the response of an organism to environmental 
stressors, and factors that regulate changes of  the proteome, transcriptome, and genome.44,49-52 In the 
history of PD research, targeted or focused metabolitic studies have been one of the areas of major 
focus. Nonetheless, systems biology emphasizes investigating multi-class metabolites at the same 
time.  
The difficulties associated with metabolomics studies include:  
1) The metabolome changes continuously and almost instantaneously in response to various 
biological challenges.  
2) Metabolites are a highly heterogeneous group of compounds, and exist over wide 
dynamic concentration ranges and have highly variable chemical and physical properties. 
3) The number of all metabolites (the metabolome) is probably much larger than other 
–omes. For example, while there are about 25,000 genes in the human genome, the 
metabolites in the human metabolome are expected to exceed 200,000.52  
Numerous techniques have been developed for measuring different types of metabolites in PD 
and other disorders. Traditional targeted metabolite analyses are generally labor-intensive and 
 9
time-consuming processes. The trend for PD or any other metabolite studies is to simultaneously 
measure as many metabolites as possible in a fast and automated fashion.  
Existing techniques that permit large numbers of metabolites to be measured simultaneously 
include nuclear magnetic resonance (NMR) spectroscopy, and tandem analytical techniques such as 
gas chromatography-mass spectrometry, i.e., GC-MS and high performance liquid chromatography 
(HPLC)-MS. These are rational tools for modern metabolomics studies. The main drawback for NMR 
spectroscopy is its low sensitivity, which is inadequate for low abundance metabolite detection.53-56 
GC-MS, prominent because of its superior resolving power and sensitivity, has the problem of its 
limited application only to those metabolites that have sufficient volatility and thermal stability.57-61 
HPLC-MS approaches, based on the revolutionary development of atmospheric soft-ionization 
techniques, capillary/nano-HPLC and ultra-performance LC (UPLC) techniques, are becoming the 
approaches of choice for modern metabolomic studies.55,62-68 
 
D. Challenges and Critical Techniques in Metabolite Studies in Animal 
Models of PD. 
‘Progress in science depends on new techniques, new discoveries and new ideas, probably in 
that order.’Sydney Brenner , Nobel Prize for Physiology or Medicine 2002.69 
Any successful analysis depends on a complete analytical system (illustrated in Figure 1-5) in 
which every part of the whole system is of equal importance. 
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Figrure 1- 5. Complete analytical system 
 
For the sampling step, animal brain tissue biopsy has been employed from the very beginning 
of PD research and is still widely used. Microdialysis, a newer technique which emerged about two 
decades ago, has shown tremendous advantages over tissue biopsy for metabolite analysis and has 
become accepted as the preferred sampling technique for studies of animal models of PD and other 
disorders where in vivo monitoring of chemicals are performed.70-73 Microdialysis is a minimally 
invasive sampling technique, and its application in clinical human research has been increasingly 
reported.74-81  
Microdialysate samples are generally considered to be much cleaner in the sense that they are 
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free from macromolecules such as proteins which, in turn, eliminates additional tedious sample 
preparation step needed for tissue analysis. More importantly, continuous in vivo monitoring of 
metabolites in almost real time is possible.  
Nevertheless, being derived from a biological system, microdialysis samples are still very 
complicated containing abundant low molecular weight compounds that pose significant challenges to 
scientists to develop analytical techniques for their identification and quantitation.    
As discussed previously, HPLC-MS is generally considered to be the method of choice for 
identifying and quantitating metabolites. Nevertheless, there are several challenges associated with 
HPLC-MS analyses of microdialysate samples. For example, microdialysate samples normally contain 
high concentrations of inorganic salts (NaCl, KCl, MgCl2, etc.) that are included in the perfusion 
solution (perfusate) in order to mimic the concentrations of these salts in biological fluids such as 
plasma and cerebrospinal fluid (CSF). Such salts are innocuous for most conventional assays utilizing 
UV-vis, electrochemical, and florescence detectors. In contrast, these salts must be completely 
removed in the case of HPLC-MS in order to protect the mass spectrometer from contamination with 
resultant loss of sensitivity or worse.82,83  The only practical method for removal of inorganic salts in 
an automated HPLC-MS analysis system is apparently on-line solid phase extraction (SPE).82,84-88  
The targeted analytes in in vivo microdialysis experiments are often present in very low 
concentrations (µM or lower), and many are unstable in the presence of oxygen or light. Typically, 
microdialysis is employed to monitor time-dependent changes in analyte concentrations in response to 
some biochemical, chemical or behavioral insult. In order to achieve this goal, sample throughput and 
handling become of ultimate concern.  
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All the above challenges and requirements demand the development of an analytical system 
which has the following capabilities:  
a) Fully automated, with minimal sample handling and very restricted or no exposure of 
samples to the external environment in order to achieve the greatest possible analytical 
accuracy and precision. 
b) High sample throughput. The system should be fast enough to monitor time-dependent 
concentration changes of target compounds in vivo. 
c) High detection power. The system should have low detection limits and the largest possible 
linear dynamic range for multi-classes of analytes.  
d) High adaptability. The system should have the ability to analyze various compounds having 
very different chemical/physical properties with minimal modification.  
e) Highly robust and reliable permitting extended periods of use.  
Besides important requirements such as full automation, microdialysis sampling, on-line SPE 
sample preparation and HPLC-MS instrumental analysis, ion-pairing (IP) is another critical technique 
for metabolite analysis in animal models of PD. Its application to on-line SPE and HPLC is the key to 
the success of the whole system. 
One of the fundamental challenges for HPLC-MS applications in metabolomic studies in 
biological samples is that metabolites exist in a wide polarity range. Traditionally, pre-column 
derivatization or ion-exchange chromatography has been required to measure highly polar or ionic 
molecules.89-91 But these techniques are difficult to integrate into a high throughput fully automated 
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system which is built for multi-class metabolite monitoring. IP-reversed phase HPLC-MS might be 
the answer for highly polar or ionic molecules.  
IP reagents have long been known for their capability to  increase the retention times of 
highly polar to ionic molecules while leaving less polar or non-polar molecules unaffected in reversed 
phase (RP) HPLC.92 This makes it possible to analyze the whole spectrum of molecules using a single 
RP-HPLC column.  
 
 
Figrure 1- 6.  Analyte properties and HPLC methods.  
 
Traditional IP reagents, principally alkylsulfonates with different alkyl chain lengths, are 
non-volatile and therefore are unsuitable for HPLC-MS. Volatile IP reagents have been studied 
intensively to cope with the rapid development of HPLC-MS techniques in recent years.24,92-98  
Typically, the volatile IP reagents for cationic analytes are perfluorinated carboxylic acids, e.g., 
trifluoroacetic acid (TFA), heptafluorobutyric acid (HFBA), nonafluoropentanoic acid (NOFPA), 
tridecafluoroheptanoic acid (TDFHA) and pentadecafluorooctanoic acid (PDFOA). For acidic analytes 
typical IP reagents are trialkylamines such as triethylamine and tributylamine. 
 14 
IP reversed-phase SPE (IP-RP-SPE) is a relatively new and less well-known technique 
compared to conventional reversed-phase or ion-exchange SPE. Nevertheless, it has the same 
mechanism as IP-RP-HPLC and has  advantages over conventional SPE that include selectivity, 
compatibility with multi-class analysis, and  direct coupling to reversed-phase HPLC analytical 
columns.99-103  
 
E. Dissertation Purpose 
The initial goals of the dissertation research was to monitor in vivo arachidonic acid 
metabolites (eicosanoids) utilizing HPLC-MS techniques. We initially focused on the instrumentation 
development and established a very specific and sensitive method which combined the techniques of 
normal phase HPLC with electron capture atmospheric pressure chemical ionization (EC-APCI). In 
these preliminary studies the impact of sample preparation and system automation was disregarded. 
However, when the HPLC-EC-APCI technique developed was applied to in vivo experiments, the 
project was severely impaired by necessary tedious manual sample pre-treatment, which involved 
labor intensive and time consuming sample collection, liquid-liquid extraction, off-line derivatization 
and multiple desolvation steps. Thus, this project yielded only limited results. Both the results and the 
method development are summarized in Chapter 7.  More meaningful than the results was the lesson 
learned that automation and on-line sample preparation were as important as instrumental analysis part 
to the complete system, especially for experiments aimed at in vivo monitoring of metabolites. 
The second stage of the research was aimed at monitoring neurochemicals and related low 
molecular weight compounds of relevance to the pathogenesis of PD in the striatum of awake rats. In 
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general, the HPLC-MS was the technique of choice for the instrumental analysis. A fully automated, 
labor free system which combined microdialysis sampling, on-line IP-RP-SPE sample preparation, 
IP-RP-HPLC separation and tandem MS/MS detection techniques was established.  
The system developed was shown to be very effective for a project aimed at monitoring 
catecholamines and metabolites in microdialysate samples collected from the striatum of awake rats. 
In the second project, where the important antioxidants glutathione (GSH) and (highly ionic) cysteine 
(CySH) were targeted, an on-line derivitization step was added before on-line SPE. With this 
modification, both GSH and CySH could be successfully profiled in vivo in the animal model of PD. 
Another in vivo project was focused on MPTP and MPP+. Thus, MPTP and MPP+ could be 
successfully monitored in rat striatal microdialysates without modification of the initial fully 
automated system. There is no doubt that this system is capable of profiling a wide range of 
metabolites simultaneously in a highly sensitive and expeditious way. 
 
F. Project Description 
The following work was conducted as presented in the following chapters. 
Chapter Two.  A fully automated system. 
A. Schematic overview diagram of the fully automated system is presented. 
B. Individual components of the system, their function, operating conditions and the system 
alignment are illustrated using a control chart and an events chart. 
C. The stability, repeatability of the fully automated system was evaluated by 9-h continuous 
measuring of different model compounds.  
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D. Time arrangement for complete in vivo animal experiments is presented and their importance 
discussed. 
Chapter Three.  On-line ion-pair reversed phase SPE 
A. Solvent front elution profile for the RP-SPE column was obtained by loop injection of 
methanol onto the SPE column the eluent being monitored by full scan MS. 
B. Theoretical consideration of SPE is discussed. Theoretical SPE breakthrough curves for 
unretained substances (salts) were calculated.  
C. Different concentrations and pH of the IP agent HFBA was applied to the SPE mobile phase, 
and their influence on IP-RP-SPE efficiency for DA is discussed. 
D. The IP agent TDFHA was tested and compared with HFBA for IP-RP-SPE efficiency on 
catecholamines and serotonin (5-hydroxytryptamine, 5-HT) and 3-methoxytyramine (3-MT).   
E. Utilizing the automated system described in Chapter Two, experiments were carried out to 
obtain breakthrough curves for the catecholamines, 5-HT, 3-MT, GSH, CySH, GSH-MPB, 
CySH-MPB, MPTP, and MPP+. SPE optimization for these compounds are discussed. 
 
Chapter Four.  In vivo catecholamines and related compounds analysis.  
A. Off line (loop injection) mass spectrometry experiments were performed to obtain parent and 
daughter ion mass spectra and to optimize selected reaction monitoring (SRM) conditions for 
the catecholamines (DA, NE and EPI), 5-HT and the metabolite 3-MT.  
B. Calibration curves were obtained utilizing the fully automated system described in Chapter 
Two. 
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C. In vitro microdialysis experiments were performed for catecholamine mixtures with different 
concentrations to determine probe recoveries. 
D. Surgical procedures were conducted to implant guide cannula in the rat striatum. 
E. Employing microdialysis, 10 mM MPTP was perfused for 30 min into the striatum of 
freely-moving rats and microdialysate samples were analyzed using the fully automated 
system described in Chapter Two. 
 
Chapter Five.   In vivo GSH/CySH analysis 
A. Off-line mass spectrometry experiments were performed to obtain parent and daughter ion 
mass spectra and to optimize SRM conditions for GSH and CySH. 
B. The fully automated system described in Chapter Two was applied for GSH/CySH standard 
solutions; the necessity for on-line derivatization is discussed. 
C. An on-line derivatization step, which utilized a home made on-line mixer, was added before 
on-line SPE. A modified schematic diagram is presented. 
D. The chemistry of the derivatization reaction is presented.  
E. HPLC-MS and HPLC-MS/MS experiments were performed to obtain parent and daughter ion 
mass spectra, and to optimize SRM conditions for GSH-MPB and CySH-MPB. 
F. Calibration curves for GSH and CySH were measured utilizing the modified fully automated 
system. 
G. In vitro microdialysis experiments were performed for standard solutions of GSH and CySH 
to obtain probe recoveries.  
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H. Surgical procedures were conducted to implant guide cannula into the rat striatum. 
I. Employing microdialysis, solutions of 10 mM MPTP, 2.5 mM MPP+, and 5 mM MPP+ were 
perfused for 30 min into the striatum of freely-moving rats and microdialysate samples were 
analyzed using the modified fully automated system described in this chapter. 
 
Chapter Six.  In vivo MPTP and related metabolites analysis 
A. Off-line mass spectrometry experiments were performed to obtain parent and daughter ion 
mass spectra, and to optimize SRM conditions for MPTP and MPP+. 
B. Calibration curves were determined utilizing the fully automated system described in Chapter 
Two. 
C. In vitro microdialysis experiments were performed for standard solutions of MPTP and MPP+ 
to obtain probe recoveries. 
D. Surgical procedures were conducted to implant guide cannula into the rat striatum. 
E. Employing microdialysis, solutions of 10 mM MPTP were perfused for 30 min into the 
striatum of freely-moving rats and MPTP, PTP, MPDP+, MPTP-N-Oxide and MPP+ levels in 
mocrodialysate were monitored using the fully automated system described in Chapter Two. 
 
Chapter Seven.  Arachidonic acid metabolites analysis by HPLC-ECAPCI-MS/MS 
A. Introduction to the arachidonic acid (AA) metabolites (eicosanoids) cascade, the metabolic 
scheme and putative relationship to PD are presented. 
B. Instrumental analysis method developed for arachidonic and its metabolites. 
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C. Off-line mass spectrometry experiments were performed to obtain parent and daughter ion 
mass spectra, and to optimize SRM conditions for AA, prostaglandin E2 (PGE2), 
prostaglandin D2 (PGD2), and prostaglandin F2α (PGF2α) 
D. Surgical procedures were conducted to implant guide cannula into the rat striatum. 
E. Employing microdialysis, microdialysate samples were collected and the basal levels of PGE2, 
PGD2 and PGF2α were measured using the method developed in this chapter. 
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Chapter Two 
 
A Fully Automated System 
 
A. Introduction 
Recently, fully automated systems utilizing HPLC-MS to study metabolites in biological 
samples have become more and more popular. Such systems usually employ an on-line SPE directly 
coupled to the HPLC-MS system. Sample collection and storage is still required isolated from the 
automated system.104-107 
On-line microdialysis, i.e., microdialysis directly coupled to an HPLC or capillary 
electrophoresis (CE) system, is also a frequently used technique. The major advantages of on-line 
microdialysis include simple sample preparation, automated analysis, and reduced exposure of 
microdialysate samples to air and light. In on-line microdialysis, the detection techniques coupled to 
HPLC or CE108-111 include UV-vis,112-117 atomic absorption spectroscopy,118,119 electrochemical,120-125 
fluorescence,126-128 laser-induced fluorescence129,130 and enzyme-based biosensing.131-137 However MS, 
as the leading detection technique for metabolites, has rarely been employed as a detection/analytical 
tool in connection with on-line microdialysis.138 The reason for this, as discussed in the previous 
chapter, is that electrospray ionization-MS (ESI-MS) is highly susceptible to the presence of salts and 
other low molecular weight impurities that are always present in biological samples.139 Integrating an 
on-line SPE procedure into the on-line microdialysis system to provide a clean sample for MS 
detection represents a potential solution to this difficulty. In this chapter, a fully automated system 
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consisting of on-line microdialysis sampling, on-line SPE and HPLC-MS is described.  
 
B. Experimental 
1. Chemicals. 
Milli-Q (Continental Water System; El Paso, TX) deionized water (18 MΩ) was used. HPLC 
grade methanol (MeOH) was obtained from Fisher Scientific (Fairlawn, NJ, USA ). 
Heptafluorobutanoic acid (HFBA, 99%), was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
HFBA is a liquid at room temperature and was used as received from the supplier without further 
purification. Tridecafluoroheptanoic acid (TDFHA, 99%), was purchased from Aldrich. TDFHA is a 
solid at room temperature (melting point 30°C). Before use, the glass bottle containing TDFHA was 
placed in an oven at ~40°C for 15 minutes to liquefy the solid. Artificial cerebrospinal fluid (aCSF) 
was water containing: 147.0 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2 and 0.85 mM MgCl2, pH 
adjusted to 7.40 by a phosphate buffer. 
Ammonium hydroxide (NH4OH) (28% in H2O, 99.99+%) was purchased from Sigma-Aldrich 
(St. Louis, MO, USA), it was diluted to ~7% with deionized water for further use. Formic acid (FA) 
(ACS grade, 88% in water) was purchased from Sigma-Aldrich. Dopamine (DA), epinephrine (EPI), 
norepinephrine (NE), serotonin (5-HT), and 3-methoxytyramine (3-MT) were also obtained from 
Sigma-Aldrich. 
 
2. Stock and Working Standard Solutions. 
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Stock standard solutions (1.0 mM) of the three individual catecholamines (DA, NE. EPI), 
5-HT, and 3-MT were prepared in water containing 0.1% FA and stored at -80oC. The working 
solutions were prepared by diluting the stock standard solution with aCSF. Thus, a 0.2 µM standard 
solution containing two catecholamines (DA and EPI; NE was not studied), 5-HT and 3-MT was 
prepared as follows: 10 µL of each of the four stock solutions was added to 960 µL of aCSF to obtain 
10 µM solution; 20 µL of the resulting solution was then added into 980 µL of aCSF to obtain 0.2 µM 
standard solution. All resulting solutions were stored in plastic vials and were passed through 0.2 µm 
centrifuge filter (NanoSEP™; VWR, USA) before use. 
 
3. Instrumentations Overview. 
An overview diagram of the automated system is shown in Figures 2-1 and 2-2. Note that the 
BAS rat housing/containment system (Raturn®; BAS, IN, USA) shown in Figure 2-1 is not included in 
Figure 2-2 because it was not an integral part of the analytical system. 
 
4.  On-line Microdialysis Sampling  
Immediately prior to microdialysis experiments, the aCSF solution was filtered through a 0.2 
µm NanoSEP™ centrifuge filter and thoroughly degassed with ultra pure helium gas. A gas tight 1000 
µL syringe (BAS Bee Stinger®, model MD-0100) was then filled with this aCSF solution. A 
microinjection syringe pump (CMA 100®; CMA, Stockholm, Sweden) was used to deliver the aCSF at 
a flow rate of 1.5 µL/min. The syringe was connected to the inlet of a CMA 12® microdialysis probe 
(4 mm membrane, MW cutoff 20,000 Da) using 0.12 mm ID × 0.65 mm OD PEEK capillary tubing 
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(BAS), with dead volume of 1.2 µL/100 mm. CMA capillary tube adapters were used to provide tight, 
close to zero internal volume, connections. Such tubing adapters were easy to use because they swell 
in 70 % alcohol and shrink in air. The outlet of the probe was connected to a microbore 10 port valve 
(Cheminert®; Valco Instruments, Houston, TX, USA) through CMA PEEK capillary tubing. The 
microdialysate from the probe was introduced into one of the two sample loops of the 10 port valve. 
The sample loops were made of 0.20 in ID × 1/16 in OD orange PEEK tubing (Upchurch, WA, USA). 
The two loops had identical length of 17.2 cm and, hence, their volume was 35.0 µL. The 10 port 
valve was controlled by a BAS Pollen-8® on-line injector controller through a Valco microelectric 
actuator.  
 
5.  Chromatographic System and MS detection. 
The on-line SPE was coupled to the HPLC by a column-switch technique shown in Figure 
2-2. A BAS PM-80® solvent delivery system was used to deliver mobile phase F to the SPE column at 
the flow-rate of 200 µL/min. A second HPLC pump, Thermal Finnigan Surveyor® MS pump (Thermal 
Corp., San Jose, CA, USA) was used to deliver mobile phases A and B (gradient) to the analytical 
column at a flow-rate of 80 µL/min. The column switch employed a 6-port valve Cheminert® (Valco) 
equipped with a microelectric actuator (Valco). This valve was controlled by the data acquisition 
program of the TSQ 7000 mass spectrometer. All connections for chromatography employed red 
PEEK tubing – 0.005 in ID × 1/16 in OD.  
Chromatograms were recorded by the Thermal Finnigan TSQ® 7000 triple quadrupole mass 
spectrometer operated in the ESI positive mode. The scan mode was selected reactions monitoring 
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(SRM). The details of the MS method development are presented in Chapter Four. The mass 
spectrometer conditions were as follows: ion source temperature 250oC; manifold temperature 70oC; 
ionization voltage 5000V; desolvation gas pressure 50 psi; a nebulization gas was not used. 
 
 
Figure 2- 1. Photograph of the fully automated system. 
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Figure 2- 2. Overall schematic of the instrument connections for the fully automated system. 
 
6.  Columns and Mobile Phases 
The analytical column was an ODS microbore 150 × 1.0 mm ID − 4 µm Hydro-RP® 
(Phenomenex, CA USA), with a Phenomenex 20 × 3.0 mm ID C18 guard column in an integrated 
guard column housing. The SPE column was an ODS microbore 14 × 1 mm ID − 3 µm, 80 Å BAS 
UniJet® guard column. The SPE column was mounted directly on the 6 port valve using a BAS 
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UniNut® male-female union to minimize dead volume as shown in Figure 2-3. 
 
 
Figure 2- 3. SPE column directly mounted on the 6 port valve. A: SPE column with a PEEK 
ferrule, B: male-female union. C: mounting to valve port, D: finished. 
  
Mobile phase F1 consisted of 5 mM TDFHA in water with the pH adjusted to 6.5-7.5 with 
NH4OH prepared as follows: 508.5 µL TDFHA was added to 500 mL of deionized water; then 
NH4OH was slowly added while the solution was stirred and the pH measured. The solution was 
filtered through a 0.45 µm nylon filter (Millipore Corporation, Bedford, MA), then degassed with ultra 
pure Helium gas before use. Mobile phase F2 consisted of 50 mM HFBA prepared similarly to mobile 
phase F1, except 3.25 mL of HFBA was added to 500 mL water. 
Mobile phase A consisted of 0.1% formic acid in MeOH, prepared as follows: 568 µL formic 
acid (88%) was added to 500 mL of MeOH. Mobile phase B consisted of 95% water (v/v) and 5% 
MeOH (v/v) containing 1.0 mM HFBA, prepared as follows: 12.5 mL MeOH was added to 237.5 mL 
water, and then 32.8 µL HFBA was added. The final pH of this solution was 2.5 (no pH adjustment 
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was necessary). The solution was filtered through a 0.45 µm nylon filter and then degassed with an 
embedded vacuum degasser in the Surveyor® MS HPLC system. Gradient: linear increase from 100% 
solvent B to 100% solvent A over10 min, 100% solvent A for 1 min, decrease to 100% solvent B over 
1 min, then 100% solvent B for 8 min. The total HPLC run time was 20 min. The flow rate was 80 
µL/min.  
 
7. Evaluation of the Stability of the Fully Automated System. 
In experiments aimed at evaluating instrument stability, the microdialysis probe was not used. 
The syringe was loaded with 1000 µL, 0.2 µM standard solution containing DA, EPI, 5-HT and 3-MT. 
The solution was pumped directly to the sample loops on the 10 port valve at 1.5 µL/min. The system 
was allowed to run unattended for 9 h 40 min. 
 
C. Results and Discussion 
 
1. System Control. 
For a fully automated system consisting of so many individual components, synchronization 
of their actions is extremely important. The control relationships of the components are summarized in 
Figure 2-4 and explained subsequently. 
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Figure 2- 4. Instrument control chart 
 
1) CMA syringe pump (microdialysis pump) and BAS solvent delivery system (SPE pump) 
worked as stand-alone instruments. Throughout experiments, the syringe pump pumped the 
perfusate at a rate of 1.5 µL/min; the SPE pump pumped mobile phase F at 200 µL/min. 
2) The BAS on-line injector controller had two controlling functions: 1) to toggle the 10 port 
valve every 20 minutes; and, 2) to simultaneously start the mass spectrometry data acquisition 
process.   
3) The TSQ 7000 mass spectrometer controlled the 6 port valve and the Surveyor MS pump 
(HPLC gradient pump) 
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2. Flow Scheme. 
The eluent flow scheme, presented in Figure 2-5, illustrates how the 10 port valve and 6 port 
valve were coordinated to achieve automated microdialysis sampling and on-line SPE for the system.  
 
 
Figure 2- 5. Flow scheme. 
 
During the experiment, the 10 port valve was toggled every 20 min. In each 20 min cycle, one 
of the loops was filled with the perfusate solution (i.e., aCSF or, in later experiments, aCSF containing 
the parkinsonian toxicant). The sample stored in the second loop was loaded onto the SPE column 
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during the first min of the cycle. Then the loop was washed for the remaining 19 min by the SPE 
mobile phase. The 6 port valve was controlled separately by the MS data acquisition system and 
independent to the 10 port valve. 
During each 20 min cycle, the 6 port valve was toggled twice. In the first event, which was 
before the first toggle occurred, the SPE column was loaded with sample which was swept out of the 
loop by the SPE mobile phase. The sample was then continuously washed with the SPE mobile phase. 
The time of loading and washing was an important factor which decided the efficiency of the on-line 
SPE, and was optimized according the properties of the target analytes. The detailed optimization 
procedures for SPE were presented in Chapter Three. Generally, washing time around 1.0 min was 
employed. During the time for sample loading and washing to the SPE column, the analytical HPLC 
column was under the initial gradient elution. At the end of SPE washing, the 6 port valve was toggled 
to another position and the second event initiated. This event lasted for 13 min. During this event, the 
targeted analytes were back-flushed onto the analytical HPLC column by the gradient and 
chromatographically separated. Usually it only took a very short time to wash the analyte molecules 
off the SPE column. The additional time was necessary for the HPLC gradient solvents to clean and 
regenerate the SPE column. The gradient theoretically reached 100% organic solvent (MeOH) in 10 
min. However, the dead volume for the HPLC system had to be considered in the experimental setting. 
Thus, the dead volume for the Surveyor MS pump itself plus the tubing connecting the pump and 
HPLC column was about 160 µL, i.e., the dead time was approximately 2 min.  Thus, 13 min was 
employed to make sure that the SPE column was thoroughly washed with 100% MeOH. At 14 min of 
the cycle, the 6 port valve was toggled again to trigger the third event.  In this event, the SPE column 
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was flushed and equilibrated with the SPE mobile phase and the HPLC column was equilibrated with 
aqueous mobile phase B prior to the next run.  
 
3. Event Flow Chart. 
The events for all instruments are presented more clearly in the Events Flow Chart (Figure 
2-6). It is important to track and synchronize all the events according to this chart in order to avoid 
confusion and mishandling since events from different instruments are intimately related to each other. 
The details of all events for each instruments is explained and discussed subsequently. 
 
 
Figure 2- 6. Events flow chart for the fully automated system. 
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1) The events of all components are strictly aligned, although each is flexible and could be 
adjusted individually. This is critical in the method development process for the fully 
automated analytical system.  
2) During experiments, each run cycle was fixed at 20 min. This was an arbitrary choice, 
partially based on previous experience in the development of an in vivo eicosanoids assay. 
Theoretically, the shorter this cycle time, the better the time resolution would be for the 
monitored analytes. Although a shorter cycle time necessarily requires higher detection power, 
it is in fact limited by the HPLC separation step, i.e., solvent gradient running time and 
column re-equilibration time. This is particularly true when the monitored analytes have large 
differences in chromatographic behavior. Since the concentrations and chromatographic 
properties of target analytes vary tremendously, the cycle time should be optimized for each 
type of analysis.  
3) The TSQ 7000 mass spectrometer performs two tasks in each cycle, i.e., data acquisition for 
the first 18 minutes, after which data acquisition is terminated to permit method loading in 
readiness for the next acquisition. 
4) The 10 port valve is toggled every 20 min. During each 20 min interval it permits the filling 
of one of the two 35 µL loops, and empties and washes the other loop.  
5) The 6 port valve performs three events in each cycle as described in detail previously. It 
should be emphasized that the first event decides how long the sample is to be loaded and 
washed on the SPE column. SPE breakthrough curves were determined by changing the time 
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of this event and measuring how much targeted substance remained after the washing step. 
Breakthrough curves and SPE efficiency are discussed in detail in Chapter Three. In our 
experiments, 1.0 min SPE washing (or 200 µL SPE solvent) was a general guideline. The 
second event decides how long the SPE column is backflushed. The last event is 
reconditioning of the column by the SPE mobile phase. In most experiments, this is 6 min or 
1200 µL of SPE mobile phase. 
6) The Surveyor HPLC pump is triggered by the mass spectrometer and run the gradient 
described previously. 
7) The syringe pump pumps the perfusate at 1.5 µL/min throughout the experiment. The SPE 
pump pumps the SPE mobile phase (isocratic) throughout the experiment. Theoretically, the 
higher the SPE flow rate, the better it is for the whole experiment, since it shortens the SPE 
process. However, this has to be optimized taking into account the back pressure and the 
lifespan of SPE columns. 
 
4.  System Stability.  
The system stability was measured during 9 h 40 min of continuous running, since typical in 
vivo monitoring experiment lasted 6-8 h, subject to the durability of the microdialysis probe. 
1) Data Processing Method. 
The extracted ion chromatography (EIC) method was applied to all HPLC-MS/MS data in 
order to obtain accurate chromatography peak parameters for every analyte. EIC is also known as 
reconstructed ion chromatography (RIC). The difference between total ion chromatography (TIC) and 
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EIC is that TIC plots the total ion current (intensity) vs. time, whereas EIC plots a single ion signal 
intensity vs. time. The mechanism of EIC is similar to selected ion monitoring (SIM), whereas SIM is 
a MS data acquisition technique, EIC is a MS data processing technique. EIC is a basic function for all 
MS data processing software. To obtain EIC for a particular ion, simply input the m/z value of the ion 
and the deviation allowed (usually ± 0.5 m/z). EIC is extremely useful when peaks are overlapped in 
total ion chromatography (TIC), as shown in Figure 2-7. 
 
 
Figure 2- 7. Data processing method. TIC and EICs for four measured analytes. 
 
In TIC chromatography (top trace in Figure 2-7), the chromatography peaks for 3-MT and 
5-HT were overlapped, but separated by their EIC (bottom two traces in Figure 2-7). 
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2) Microdialysis sampling delay effects.  
 
Figure 2- 8 Chromatographies for the first three runs. 
 
Because of the very low perfusion flow rate (1.5 µL/min), the dead time must be carefully 
considered in on-line microdialysis experiments. For example, in Figure 2-8 the first run shows no 
signal because when it was started, the syringe pump began pumping the standard solution, hence no 
sample reached the sampling loop. Nevertheless, the data of the first run was valuable since it 
provided the mobile phase blank data. In the second run, although the sample loop had been 
continuously filled with analytes for 20 min, the dead volume between syringe and the sample loop 
has to be taken into account. For a typical 40 cm length of capillary PEEK tubing for the connection, 
the dead volume was ~4.8 µL. However, any connections, syringe needle and the pathway inside 10 
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port valve contributed to the dead volume. Thus, the total dead volume was much larger than 4.8 µL. 
Accordingly, it was no surprise that the signal intensity (peak area) for the second run was only ~50% 
of that measured for the third run. From the third run on, the signal intensity became constant. Thus 
stability was measured by comparing chromatograph peak areas for each analyte sample during the 3rd 
to the 29th run (totally 9-h).  
 
3) System Stability.  
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Figure 2- 9. System stability test: EPI. The green dotted lines are the maximum, mean 
and minimum for all data. The red dotted line is the linear fit for all data. 
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Figure 2- 10. System stability test: DA. The green dotted lines are the maximum, mean and 
minimum for all data. The red dotted line is the linear fit for all data. 
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Figure 2- 11. System stability test: 3-MT. The green dotted lines are maximum, mean and 
minimum for all data. The red dotted line is the linear fit for all data. 
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Figure 2- 12. System stability test: 5-HT. The green dotted lines are maximum, mean 
and minimum for all data. The red dotted line is the linear fit for all data. 
 
Substance Peak area mean ×106 SD ×106 SEM ×106 
EP 5.18 0.177 0.034 
DA 2.00 0.051 0.0098 
3-MT 1.96 0.075 0.0051 
5-HT 0.464 0.018 0.0035 
Table 2- 1.  System stability statistics data. 
 
Figure 2-9 − 2-12 are plots of HPLC peak area expressed as the percentage of the average of 
27 runs against time. The red dotted lines are the linear fit of the data and show the overall trend for 
the signals. For EPI, the overall trend for the signal was to decrease. For DA, no obvious trend was 
observed. For 3-MT and 5-HT the trend for the signal was to increase. The mechanisms behind these 
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trends were subjected to further investigation. Putatively, the declining trend for EPI might be related 
to its lower stability than the other analytes, meaning the actual EPI concentration in perfusate 
declined with time. The increasing trend for 3-MT and 5-HT could be caused by their higher affinity 
to the reversed phase SPE column, since both of them are lower polarity molecules. Thus, they could 
have a tendency to accumulate on the SPE column and subsequently cause increasing signals for later 
runs.  Nevertheless, the variations observed for all analytes were small (Table 2-1). Thus, it was 
concluded that the fully automated system was a high precision system with very good stability. 
 
5. Time Arrangement for In Vivo Experiments Utilizing the Fully Automated 
System. 
The fully automated system was largely labor free, with high precision and high sample 
throughput. Nevertheless, careful time arrangement for the whole in vivo experiment was necessary in 
order to maximize the usefulness of the system and to minimize human error. Figure 2-13 describes 
the experimental schedule from ordering the animal to the end of in vivo experiments. Human 
interactions are shown in the gray boxes; these actions are potentially subject to further automation. 
Some of the actions, such as drug perfusion, can be automated with an extra electronic controlled 
device. Some of the actions, including placing the microdialysis probe in a standard solution (in vitro 
examination) and then to an aCSF blank solution (in order to be flushed and cleaned), could be 
automated with the help of robotic devices. For the remainder of the actions, such as surgery and 
implanting the microdialysis probe into an awake rat are difficult to automation, at least at the present 
time.   
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Figure 2- 13. Time arrangement for in vivo experiments utilizing the fully automated system. 
 
D. Conclusions 
In this chapter, a fully automated system combining on-line microdialysis sampling, on-line 
SPE and HPLC-MS techniques was constructed. The coordination of the components is illustrated by 
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the control relation chart, eluent flow chart and event flow chart. The stability of the system was tested 
by 9 h 40 min of continuous, unattended running. The system was proved to be stable, labor free and 
had high throughput. The system therefore has the potential to provide an important research tool for 
in vivo monitoring of all kinds of metabolites, which will be demonstrated in later chapters. 
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Chapter Three 
 
On-line Ion-pair Reversed Phase Solid Phase Extraction 
(IP-RP-SPE) 
 
A. Introduction 
Ion-pair (IP) techniques held the key to the success of the automated in vivo monitoring project. 
In this project, IP was intensively used in RP-SPE to clean up and pre-concentrate analytes in 
microdialysate samples. IP was also applied to HPLC in order to improve retention for targeted 
analytes.  
The mechanism for ion-pairing is quite straightforward:140-144 IP reagents contain a nonpolar 
portion, usually a long chain aliphatic hydrocarbon (perfluorination is employed in order to increase 
the volatility of the agent), and a polar portion, such as an acid or base. The polar portion of the IP 
reagent interacts with the analyte counter-ions, forming an ‘‘ion-pair.’’ The nonpolar portion interacts 
with the nonpolar reversed phase media, usually the C18 hydrocarbon chain of the 
octadecylsiloxane-bonded silica surface. Retention of an analyte may be enhanced by increasing the 
carbon chain length of the IP reagent and by increasing the concentration of the IP reagent. 
In principle, many volatile organic acids, bases, or salts could be used as IP reagents in 
RP-HPLC-MS techniques.145 Among them, formic acid (FA), acetic acid (AA), ammonium acetate 
(NH4OAC) are widely employed. However, such compounds are more properly considered as pH 
modifiers or buffer additives than IP reagents. Indeed, their IP functions are weak owing to the very 
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short nonpolar segment of their structures. Among the IP reagent arsenal, trifluoroaectic acid (TFA) is 
the most well-known and widely used volatile IP reagent, especially in the field of peptide and protein 
analysis.146 Larger analogs of TFA are more useful for small, very polar or ionic substances.94,147-154  
Among them, HFBA and TDFHA are the most popular.94,155-157  
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Figure 3- 1. Chemical structures of three IP agents 
 
The major limitations of IP reagents is their propensity for signal suppression in ESI-MS.158 
Nevertheless, many methods to address this problem have been developed including post-column 
organic solvent or acid addition.159 In the present study, however, high concentrations of a moderately 
strong IP reagent such as HFBA or a very strong reagent such as TDFHA at low concentrations were 
used for the SPE process, while only very low concentrations (1mM) of HFBA were used in HPLC 
mobile phases. Thus, the amount of IP reagent that entered the mass spectrometer was kept minimal. 
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This approach benefited from prudent selection of the HPLC column (Phenomenex Synergi 
Hydro-RP®). The separation properties of this column are based on a mixed mechanism. While the 
column stationary phase basically consists of a nonpolar C18 reversed phase, the unbound silanol 
groups on the silica are end-capped with a polar functional group. This arrangement results in the 
column exhibiting good retention for both non-polar and highly polar compounds.160-164 Nevertheless, 
for extremely polar and ionic compounds, an IP reagent was still needed in order to obtain reasonable 
retention of the target analytes, although the minimum amount of IP reagent needed to effect 
appropriate retention was employed. In our experiments, ESI-MS signal suppression was not 
prominent and, hence, it was not necessary to devise strategies to address this issue.  
 
B.  Experimental 
1. Chemicals and Chromatographic Conditions. 
Most chemicals and chromatographic conditions were the same as described in detail in 
Chapter Two. MPTP and MPP+ were purchased from Research Biochemicals International (RBI; 
Natick, MA). Reduced glutathione (GSH) and cysteine (CySH) were obtained from Sigma. 
GSH-MPB and CySH-MPB were produced as described in Chapter Five.  Several more SPE mobile 
phase solutions were prepared and tested. These SPE mobile phases were: 
1.) Mobile phase F3, water containing 0.1% FA 
2.) Mobile phase F4, water containing 20 mM NH4OAC. 
3.) Mobile phase F5, water containing 25 mM HFBA, pH 2.5. 
4.) Mobile phase F6, water containing 50 mM HFBA, pH 2.0. 
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5.) Mobile phase F7, water containing 50 mM HFBA; pH was adjusted to 4.8 with NH4OH. 
 
2. Standard Solutions. 
Stock standard solutions were prepared and stored as described in Chapter Two.  A 1 µM DA 
standard solution was prepared as follows: 10 µL of 1 mM DA stock standard solution was added to 
990 µL of aCSF; 100 µL of this solution was then added to 900 µL aCSF. The 1 µM standard solution 
containing three catecholamines (DA, NE, EPI), 5-HT and 3-MT was prepared as follows: 10 µL of 
each of five stock standard solutions (each 1mM) was added to 950 µL aCSF; 100 µL of the resulting 
solution was added to 900 µL aCSF. All solutions were stored in plastic vials and were passed through 
0.2 µm centrifuge filter (NanoSEP™, VWR, USA) before use. The 1 µM standard solutions for 
MPTP, MPP+, GSH, and CySH were prepared similarly. All aCSF solutions were degassed with He 
sparging. 
 
3. Basic Chromatographic Properties of the SPE Column: Dead Volume and 
Solvent Front Profile. 
These experiments focused only on SPE and, hence, the fully automated system was modified 
as follows: 
1)  The HPLC pump, HPLC column and microdialysis instrumentation were not used. 
2)  PEEK tubing (Upchurch), 0.005 in ID × 1/16 in OD, was used to connect the TSQ 7000 
MS ion source inlet and port 6 on the 6-port valve; the 6-port valve was set to sample load 
 46 
and cleaning position at all times so that the SPE column was directly connected to the 
mass spectrometer during experiments.  
3)  An injection adapter was installed on port 1 of the 10-port valve so that samples were 
manually loaded into the sample loop.  
4)  The injection was controlled by manually pushing the trigger button on the BAS on-line 
injection controller. After the sample was loaded the button was pushed to toggle the 
10-port valve so that the sample was delivered to the SPE column. At the same time the 
TSQ 7000 MS was triggered to initiate data acquisition. The SPE eluent was continuously 
monitored by MS. 
5)  The SPE mobile phase used in this experiment was mobile phase F3.  
With the above modification, 35 µL MeOH was injected and the SPE eluent was monitored by 
MS in the full scan (50-500 m/z) mode. 
 
4. Influence of Different Ion-Pair Agents on the SPE Efficiency.   
Using the above instrumental arrangement, SPE mobile phases F3, F4, F5 were tested. The 
1 µM DA (as model compound, MW = 153.1) standard solution was manually injected and the SPE 
eluent monitored by MS in the single ion monitoring (SIM - 154.1) scan mode.  
 
5.  Influence of HFBA Concentration and pH on SPE Efficiency. 
The instrumentation used in these experiments was the same as above.  SPE mobile phases 
F6, F7 and F1 were tested.  The 1 µM DA standard solution was manually injected and the SPE 
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eluent monitored by MS in the single ion monitoring scan mode. 
 
6. SPE Breakthrough Curves for Catecholamines, 5-HT and 3-MT Using 
HFBA- and TDHFA- Based Mobile Phases. 
The fully automated system described in Chapter Two was employed. The standard solution 
containing a mixture of 1 µM catecholamines, 5-HT and 3-MT was perfused by a syringe pump. The 
SPE wash times were programmed between 0.2 and 2.5 minute, using 0.2 or 0.5 min increments for 
each step. The first experiment employed mobile phase F1. This was then repeated using SPE mobile 
phase F2. The mass spectrometer was set to the selected reactions monitoring (SRM) scan mode. 
Detail of SRM settings will be presented in Chapter Four. 
 
7. SPE Breakthrough Curves for MPTP and MPP+ 
Using the fully automated system (Chapter Two) and mobile phase F2, the standard mixture 
solution of MPTP and MPP+ (each 1 µM) was perfused using a syringe pump. The SPE wash times 
were programmed between 0.2 and 3.0 min in 0.2 min increment. MS SIM scan was employed where 
the ion of 174 m/z was monitored for MPTP and 170 m/z for MPP+.  
 
8. SPE Breakthrough Curves for GSH, CySH, GSH-MPB and CySH-MPB.  
Using the fully automated system (Chapter Two) and mobile phase F2, a standard solution of 
GSH and CySH (1 µM each) was perfused by a syringe pump. The SPE wash times were programmed 
between 0.3 and 3.0 minute in 0.2 min increments. GSH and CySH in the HPLC eluent were 
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monitored by MS in the SRM mode. Using the modified fully automated system (Chapter Five), the 
10 µM standard solution for GSH, CySH together with the 5mM MPB solution (on-line derivatization) 
were perfused by a syringe pump. GSH-MPB and CySH-MPB were monitored by MS in the SRM 
mode. 
 
C. Results and Discussion 
 1. Solvent Front of the SPE Column and Theoretical Considerations. 
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Figure 3- 2. Solvent front profile for the SPE column, showing the retention time (0.28 min) 
and peak width at half maximum (FWHM) (0.17 min). 
 
The dead time (td) for the SPE was 0.28 min at a flow rate (r) of 200 µL/min. Thus, the dead 
volume (V) was calculated as V = td × r = 56 µL. The full width at half maximum (FWHM) of the 
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peak was 0.17 min. The simplest theoretical simulation was to fit the chromatographic peaks to a 
normal distribution curve:  
)
2
)(
exp(
2
1
2
2
σpiσ
dttS −−=
 
where FWHMFWHM 425.0
2ln22
1
≈=σ
 
Using the experimental values of td and σ, a normal distribution simulation was carried out and is 
presented in Figure 3-3. 
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Figure 3- 3. Normal distribution curve (red dashed line) superimposed on the 
experimental SPE solvent front profile (black curve) 
 
With this simulation it was possible to calculate the theoretical breakthrough curve for the 
solvent front for salts. A breakthrough curve is a graphic representation of the recovery rate of the 
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monitored analyte relative to the time employed to wash the SPE column. Measuring and studying the 
breakthrough curve was important to justify the efficiency and to optimize the SPE. For HPLC-MS 
techniques, the experimental measurement of breakthrough curves for salts and other unretained small 
molecules is difficult, if not impossible.  
Thus, the theoretical breakthrough curve is a tool to study the behavior of salts in SPE 
processes. From the normal distribution formulation, the breakthrough curve can be derived as:  
)]
2
(1[50
σ
dtterfR −−×=
 
where R is the SPE recovery, expressed as a percentage; and erf is the Gaussian error function. Using 
experimental td and σ values, the breakthrough curve is presented in Figure 3-4. 
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Figure 3- 4. Theoretical breakthrough curve for solvent front (salts). The wash time 
required to remove 99.9% of salts was 0.52 min. 
 
 From the simulation data sheet (not shown), a 0.52 min wash time was necessary to wash 
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out 99.9% of salts. It should be noted, however, that 0.52 min is the theoretical minimal time. In 
reality, longer washing times are always necessary. One consideration is that there are endogenous 
matrix compounds which are not totally unretained and, therefore, longer wash times are required to 
remove these substances.  
If a recovery of 99.9% is assigned for a compound with a maximum of 0.1% of the salts 
remain left on the SPE column, and it can be calculated from theoretical simulations (process not 
shown) that a minimum retention time of 0.75 min is required for that compound, which corresponds 
the retention factor K: 
68.1=−=
d
dr
t
ttK
 
2. Influence of Different Ion-Pair Reagents on SPE efficiency. 
 
 
Figure 3- 5. DA SPE eluent profiles for different IP reagent-modified SPE mobile phases. From 
left to right: solvent front (blue dotted line); mobile phase F4 (solid black line); mobile phase F3 
(solid violet line) and mobile phase F5 (solid red line). 
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Figure 3- 6. Theoretical breakthrough curve for solvent front (salts) and DA in different mobile 
phases. From left to right: solvent front, mobile phase F4 (NH4OAC), mobile phase F3 (FA) and 
mobile phase F5 (HFBA). 
 
The dotted line in Figure 3-6 indicates the situation when the theoretical minimal wash time 
(0.52 min) is applied. Under these conditions, only mobile phase F5 met the requirement for a DA 
recovery of 99.9+%. NH4OAC and formic acid were not adequate IP reagents to extract DA. HFBA 
was a good IP reagent for DA in IP-RP-SPE. 
 
3. HFBA Concentration and pH Influence on SPE Efficiency for DA. 
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Figure 3- 7. HFBA concentration and pH influence on DA extraction. The numbers represent 
HPBA concentrations and pH. 
 
The experimental results displayed in Figure 3-7 show that increasing the HFBA 
concentration from 25 mM to 50 mM decreases the retention time for DA from 1.49 to 1.36 min. 
Increasing pH greatly increased retention time. When the pH was increased to 6.5, no detectable DA 
was washed out from the SPE column in 5 min. The conclusion, therefore, is that the concentration of 
the IP reagent has a limited influence on SPE efficiency, while pH has a tremendous influence. This is 
reasonable because: 1) the concentration of IP was always several orders of magnitude greater than 
that of the analytes; and, 2) in order to have the ability to form an ion-pair the IP reagent must be in its 
ionic form, meaning it has to be deprotonated. Deprotonation is always facilitated by higher pH.  
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4. Experimental Breakthrough Curves for Catecholamines, 5-HT and 3-MT. 
Previous experiments showed that direct measurement of SPE eluent profiles for the analytes 
was a useful technique to evaluate SPE efficiency. However, when the analytes were ‘truly’ retained 
on the SPE column, e.g., DA in mobile phase F1, an elution profile cannot be obtained. Nevertheless, 
experimental measurement of the breakthrough curve was feasible thus providing a better way to 
optimize SPE conditions. In experiments measuring breakthrough curves, assigned wash times were 
applied to the targeted compound, then it was backflashed out of the SPE column and subsequently 
analyzed by HPLC-MS. The advantages of direct breakthrough curve measurements include: 
1)   A breakthrough curve can be measured for most compounds. The experimental set-up is 
straightforward and easy to perform with the fully automated system. During the 
experimental design, a sample acquisition queue was designed such that all acquisitions in the 
queue were identical except the SPE wash times were programmed to increase (or decrease) 
in a stepwise fashion. The details of how to change the wash time is described in Chapter Two. 
Once the acquisition queue was started, the whole experiment was fully automated and 
unattended.  
2)   The system setting used to measure breakthrough curves was the same as the in vivo 
experiments. Thus, SPE condition optimization directly related to in vivo experimental 
results. 
3)   When measuring breakthrough curves, salts were washed from the sample before further 
analysis thus protecting the MS detector 
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Figure 3- 8. A typical data in the breakthrough curve measurements for catecholamines, 5-HT 
and 3-MT. Extracted ion chromatography (EIC) was applied for all 5 analytes. 
 
 
Figure 3- 9. Breakthrough curves for catecholamines, 5-HT and 3-MT in mobile phase F1. 
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The above graphs show breakthrough curves for the three catecholamines, 5-HT and 3-MT 
using SPE mobile phase F1. Clearly, NE was not retained very well, meaning that most NE actually 
co-eluted with the solvent front or salts. EPI had a much better (longer) retention time than NE 
although a shorter wash time (~0.7 min) was required to achieve a high recovery. The optimal wash 
time for DA was around 1.2 min. For 3-MT and 5-HT, wash times longer than 2 min were preferable.  
Theoretically, the recovery rate always decreases with wash time. However, it was commonly 
noted in SPE experiments that the recovery rate increased in the early stages of washing, as shown on 
the graph for DA, 3-MT and 5-HT (Figure 3-9). The explanation for this relies on the fact that the 
detection of many compounds is affected by the matrices that co-elute. Prolonged wash times help to 
remove these matrices. 
From the above experiment, NE could not be analyzed using mobile phase F1. Accordingly, 
another experiment was carried out using mobile phase F2, where a much stronger IP reagent, TDFHA, 
was employed. 
The following graphs show the breakthrough curves for five targeted analytes − three 
catecholamines (DA, EPI and NE), 5-HT and 3-MT. They were analyzed by the fully automated 
system (Chapter Two) using SPE mobile phase F2 (TDFHA). All of the targeted analytes were 
recovered to a satisfactory extent. From the graph, a wash time of 1.0 to 1.2 min was an optimized 
practical choice for the analysis of these compounds.  
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Figure 3- 10. Breakthrough curve for catecholamines, 5-HT and 3-MT in mobile phase F2. 
 
5. Breakthrough Curves for MPTP and MPP+ 
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Figure 3- 11. Breakthrough curves for MPTP and MPP+ using mobile phase F2. 
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The above graph (Figure 3-11) show MPTP and MPP+ breakthrough curves in mobile phase F2. 
An SPE wash time of 0.8 −1.0 min was a practical choice. 
 
6. Breakthrough Curves for GSH, CySH, GSH-MPB and CySH-MPB 
 Sometimes even a very strong IP reagent such as TDFHA is unable to permit the SPE column 
to retain strongly ionic molecules. This effect was observed when analyzing GSH and CySH (Figure 
3-12). Accordingly, it was necessary to derivatize GSH and CySH with MPB in order to enable the 
SPE extraction. A full description of the derivatization process is presented in Chapter Five. The 
breakthrough curves for GSH, CySH, GSH-MPB and CySH-MPB are summarized in Figure 3-12. 
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Figure 3- 12. Breakthrough curves for GSH, CySH, GSH-MPB and CySH-MPB using 
mobile phase F2. 
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As illustrated in Figure 3-12, GSH and CySH were co-eluted with the solvent front in mobile 
phase F2 and, consequently, could not be analyzed. However, following derivatization, GSH-MPB and 
CySH-MPB were extracted very well by SPE. A wash time from 1.8 to 2.0 min was a practical choice.  
 
D. Conclusions 
The use of IP reagents in SPE and HPLC was the key to the successes of fully automated 
system. Optimization of the SPE process for any analyte is the most important step for the whole 
experiment. In order to determine the optimum SPE conditions, different IP agents were tested. 
Experiments showed that pH was the most important factor relating to IP efficiency. HFBA exhibited a 
very good ability to increase SPE efficiency for most catecholamines, 5-HT and 3-MT. However, 
HFBA was inadequate for NE. TDFHA is the reagent of choice for IP-RP-HPLC. However, TDFHA 
was inadequate for very ionic molecules such as GSH and CySH. Thus, other approaches such as 
pre-SPE derivatization were necessary in order to analyze GSH and CySH. During SPE optimization, 
breakthrough curve measurement was a powerful tool. 
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Chapter Four 
 
Fully Automated On-line Sample Cleanup and HPLC-MS/MS 
Determination of Catecholamines and Related Compounds in Rat 
Brain Striatum: An In Vivo Microdialysis Study.  
 
A. Introduction 
Catecholamines such as dopamine (DA), norepinephrine (NE) and epinephrine (EPI), are 
naturally occurring molecules that act as neurotransmitters and hormones regulating multiple 
physiological processes in organisms.165 In animal brain, abnormal physiological concentrations of 
these compounds are often related to neuroendocrine disorders.166-169 Massive release of DA is one of 
the characteristic effects observed  in response to the administration of certain widely used 
neurotoxicants that mimic, in experimental animals, the selective neurodegeneration that occurs in 
Parkinson’s disease (PD).170,171 Catecholamine metabolism is also believed to provide an important 
source of free radicals.172 For example, during the monoamine oxidase-B (MAO-B)-mediated 
degradation of DA a byproduct is H2O2 that can serve as a source of the highly cytotoxic hydoxyl 
radical (HO⋅) by transition metal catalyzed Fenton or Haber-Weiss chemistry.173-175 Accordingly, 
accurate, selective in vivo measurement of catecholamine and related metabolite levels in biological 
systems could be important in pathological studies of many diseases. In our laboratory, 
catecholamines and related metabolites in animal models of PD have been routinely analyzed. 
Historically, the methods for catecholamine and related metabolites analyses in biological fluids have 
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primarily utilized HPLC with electrochemical176-179 or fluorimetric180-182 detection. However, such 
methods are unable to provide unequivocal identification of analytes and require considerable 
analytical skills. More recently, mass spectrometry (MS)-based methods, particularly HPLC-MS, have 
begun to be employed for analysis of catecholamines and related metabolites in biological 
samples183-189 In this chapter, a fully automated system combining microdialysis sampling, on-line 
IP-RP-SPE sample preparation, IP-RP-HPLC separation and tandem MS/MS detection techniques has 
been developed and employed to monitor in vivo three catecholamines (NE, DA and EPI), 5-HT and 
3-MT.   
  
B. Experimental 
1. Chemicals and Chromatographic Conditions. 
Chemicals and chromatographic conditions were the same as described in Chapters Two and 
Three. One extra HPLC mobile phase was tested: mobile phase B2 which was water containing 0.1% 
FA. 
 
2. Standard Solutions. 
Stock standard solutions for NE, DA, EPI, 5-HT and 3-MT (1 mM) were prepared and stored 
as described in Chapter Two.   
Five 1 µM standard solutions for individual analytes were prepared as follows: 10 µL of each 1 
mM individual stock solution was added to 990 µL aCSF to obtain 10 µM solution of all compounds; 
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100 µL of this solution was added into 900 µL aCSF to obtain a solution containing 1 µM of each 
compound.  
A series of calibration standard mixture solutions (1000 nM, 500 nM, 100 nM, 50 nM, 20 
nM, 5 nM, 2 nM, 1 nM and 0.5 nM) was prepared as follows: a 1 µM standard solution containing NE, 
DA, EPI, 5-HT and 3-MT was prepared the same way described above. 500 µL of this solution was 
added to 500 µL aCSF to obtain a 500nM solution; 100 µL of 500 nM solution was added into 400 µL 
aCSF to obtain a 100nM solution; 500 µL of 100 nM solution was added into 500 µL aCSF to obtain a 
50 nM solution; 400 µL of 50 nM solution was added into 600 µL aCSF to obtain  a 20 nM solution; 
200 µL of 20 nM solution was added into 600 µL aCSF to obtain a 5 nM solution; 400 µL of 5 nM 
solution was added into 600 µL aCSF to obtain a 2 nM solution; 500 µL of 2 nM solution was added 
into 500 µL aCSF to obtain a 1 nM solution; 500 µL of 1 nM solution was added into 500 µL aCSF to 
obtain a 0.5 nM solution.  All solutions were stored in plastic vials placed on ice in a covered 
container, and were passed through 0.2 µm centrifuge filter before use.   
The standard mixture solutions for in vitro experiments (500 nM, 100 nM and 50 nM, 1000 
µL each) were prepared in the same manner described above. 
 
3. Selected Reaction Monitoring (SRM) Optimization.  
In SRM optimization experiments, off-line loop injections were performed and the fully 
automated system was not employed. The 6 port valve was modified as a loop injector as follows: a 10 
µL PEEK sample loop (Upchurch) was installed on ports No. 2 and 5; a injection adapter was installed 
on port No. 4; port No. 1 was connected to the HPLC eluent; port No. 6 was connected to the mass 
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spectrometer; port No. 3 led to waste. Mobile phase A (100%) at a flow rate of 100 µL/min was 
employed.  
MS full scan: 10 µL of 1 µM individual standard solutions were injected, while MS scan 
range of m/z = 50 to 500 was employed in order to obtain parent ion information. Other MS 
conditions were the same as described in Chapter Two. 
MS/MS scan conditions: 10 µL of 1 µM individual standard solutions were injected. The 
collision gas was ultra high purity argon; the pressure of argon in the collision cell chamber was 2.7 
mTorr. Other MS conditions were the same as described in Chapter Two. In each experiment, a data 
acquisition sequence was established in which the collision induced dissociation (CID) energy was 
programmed to increase in a stepwise fashion from 10 eV to 50 eV in 5 eV steps, with each step 
lasting 2.5 min. The total experiment lasted 22.5 min. For each step, one injection of the standard 
solution was manually performed. MS/MS mass spectra and chromatograms were collected 
continuously. This type of scheme was called CID energy-step-increase experiment. 
 
4. Influence of Different MS Scan Modes on the HPLC-MS Signal/Noise 
Ratio. 
In these experiments the instrumentation was the same as described above except that:  a) a 
Phenomenex Synergi™ Hydro-RP column was installed between port No. 4 and the MS ion source 
inlet, and, b) the HPLC eluent was 100% mobile phase B2 in isocratic condition. Three MS scan 
modes were employed: a) full scan, 50 to 500 m/z; b) SIM scan, m/z =154.1 and, c) SRM scan, 
154.1→137.1@16eV. For each experiment, 10 µL of the 1 µM DA standard solution was injected. 
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5. Calibration Curves  
The fully automated system (Chapter Two) was employed for calibration curve 
determinations. However, the microdialysis probe was not used and the BAS gastight syringe was 
loaded with the standard mixture solution. The solution was perfused directly to the sample loop on 
the 10-port valve at a rate of 1.5 µL/min. Experiments were performed starting from the lowest 
concentration (0.5 nM) to the next higher concentration and so on. For each concentration, at least six 
runs were performed with the first two runs being considered as equilibration processes. 
 
6. In Vitro Microdialysis Experiments 
 Utilizing the fully automated system (Chapter Two), the syringe was loaded with aCSF. 
The tip of the microdialysis probe was immersed into standard mixture solutions stored in plastic vials. 
The recovery was expressed as the percentage ratio of the measured dialysate concentration compared 
to the known concentration of the in vitro standard solutions.  Experiments were performed starting 
from the lowest in vitro concentration (50 nM) to the next higher concentration and so on. For each 
concentration, at least six runs were performed, the first two runs being considered equilibration 
processes.  
 
7. Animals and Surgical Procedures 
All animal experiments were performed in strict accordance with the protocols approved by 
the Institutional Animal Care and Use Committee at the University of Oklahoma. Adult male albino 
Sprague-Dawley rats (Harlan Sprague-Dawley, Madison, WI) weighing 320-350 g were used.  Upon 
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arrival they were allowed 5−7 days to become equilibrated with their new environment. Animals were 
housed individually in cages with bedding (Sani Chips®; P.J. Murphy Forest Products, Montville, NJ) 
and free access to food (Lab Diet® #5008 Formulab Diet; PMI® Nutrition International, LLC; 
Brentwood, MO) and water. The room that housed the rats had a 12 hour light-dark cycle. During the 
equilibration period, rats were brought into the laboratory for 4 −6 h each day prior to surgery. The 
purpose of this was to allow the rats to become accustomed to the smell, noises and handling of the 
researcher prior to surgery. 
On the day of surgery, all rats were weighed, and the heaviest in the group was selected for 
the first surgical procedure. The rat was pre-anesthetized with diethyl ether (in a desiccator) prior to 
injection of the anesthetic (ketamine, 85.72 mg/kg; ca. 0.3 mL) and analgesic (xylazine, 5.72 mg/kg; 
ca. 0.2 mL). Ten minutes after the initial anesthesic/analgesic, animals were tested for limb reflex by 
pinching the muscles in its hind legs with tweezers. If the animal was not completely unconscious, an 
additional dose of anesthesic/analgesic at 67% of the original dose, i.e., ~0.2 mL of ketamine and 
~0.15 mL of xylazine was administered. During surgery, the animal’s consciousness was checked 
periodically and additional doses of ~0.2 mL ketamine and ~0.15 mL xylazine were administered if 
limb reflex was exhibited. Animals were placed in a stereotaxic instrument (Lab Standard™, Stoelting, 
Wood Dale, IL) with the nose bar positioned 3.3 mm below the interaural line.  Sterile eye lubricant 
(Moisture Eyes™ PM; Bausch and Lomb, Rochester, NY) was applied to the animal's eyes for 
protection.  The scalp was trimmed of excess hair and sterilized with 70% ethanol.  A midsagital 
incision was made with a surgical scalpel and the skull was exposed.  With the help of the stereotaxic 
instrument, an initial hole was made above the right striatum (8 mm lateral and 0.5 mm anterior to 
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bregma). The hole was made with an electric drill handpiece system (XL-30W; Osada Electric Co., 
LTD, Tokyo, Japan) using a surgical trephine drill bit (BAS). Three smaller trapenizations were made 
in the area surrounding the initial holes and cranial screws (Plastics One, Roanoke, VA) were secured 
(1 mm depth below the surface of skull) in these locations. The microdialysis probe guide/dummy 
cannula (CMA-12) was implanted into the initial hole location, with the tip positioned 3.4 mm below 
dura.  The probe guide/dummy cannula was secured to the skull by means of the three screws and 
cranioplastic cement (Plastics One). 
 At the end of surgery, the incision was closed with two sutures using monofilament 
polyglyconate synthetic absorbable sterile surgical suture (Maxon 5-0, 17 mm; Davis + Geck, 
Danbury, CT).  A collar (Bar-Lok® Cable Ties; Avery Dennison, Framingham, MA) was fastened 
around the animal's neck.  The animal was then transferred to its own cage and left undisturbed for 
1−2 days to recover with food and water provided.  Two days before microdialysis experiments, 
animals were placed in a bedding-lined 40 cm diameter Plexiglas bowl seated on a BAS Raturn during 
the daytime to become accustomed to the surrounding in preparation for in vivo microdialysis studies.   
The animal's collar was attached to a tether (with the ability to move freely) and it had access to food 
and water ad libitum through the study.  
 
8. In Vivo Microdialysis. 
The in vivo microdialysis experiment utilized the fully automated system and generally 
followed the protocol described in Chapter Two. The following presents the detailed step-by-step 
procedure: 
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1)  In vivo experiment preparation.  
A new microdialysis probe was prepared for use according to the manufacture’s (CMA) 
recommendations (not shown).  The aCSF solution was filtered, degassed (He sparging) and then 
transferred to the BAS 1000 µL syringe. A 100 nM standard mixture solution (for in vitro examination) 
was prepared as described previously. A TSQ 7000 MS data acquisition queue was established. The 
queue contained all the data acquisition sequences needed for in vitro examination, the aCSF blank 
wash, and in vivo microdialysis experiments. For a typical (ca. 9-h) experiment, a total of 27 data 
acquisition sequences were contained in the queue. The first 3 sequences were assigned for in vitro 
studies (probe recovery measurements), followed by 3 acquisitions assigned for aCSF blank washes. 
Basal neurochemical level monitoring usually required 6−9 acquisitions (ca. 2−3 h). Drug perfusion 
began at the same time that the last basal acquisition was started. The remaining 12−15 acquisitions (4 
−5 h) were for the in vivo microdialysis experiments.  
If necessary, individual data acquisition sequences could be added to or deleted from the 
queue even after the acquisition had begun. The instrumentation method, which defined the SPE 
loading and wash time, HPLC gradient and all MS parameters etc., was embedded in the individual 
sequences and could be modified during the experiment. This feature of flexibility was extremely 
useful for real-time monitoring experiments. Because experimental settings could be modified in real 
time according to the newest data acquired, it was not necessary to halt the whole experiment.   
2)  In vitro examination. 
Approximately 20 min after the syringe pump began perfusion of aCSF, the acquisition queue 
was started and the microdialysis probe was dipped into the standard mixture (DA, NE, EPI, 5-HT, 
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3-MT) solution. This step was designed to determine both the microdialysis probe recovery and to 
establish that the entire system was operating correctly. 
3)  aCSF blank wash 
When the probe recovery was in a satisfactory range, the microdialysis probe was taken out 
from the in vitro standard mixture solution, rinsed briefly with deionized water and placed into fresh 
aCSF. During this period, aCSF continued to be pumped through the probe in order to flush out any 
trace standards.  
4)  In vivo basal neurochemical level monitoring. 
Once the signal (i.e., HPLC peaks) for standards disappeared from the aCSF wash solution the 
dummy probe was removed from the guide cannula (in the animal) and replaced by the microdialysis 
probe with the tip being positioned 7.4 mm below dura. Throughout microdialysis experiments, the rat 
was attached to a tether in a bedding-lined BAS Raturn and, therefore, was able to move freely, and 
had access to food and water ad libitum. 
5)  Drug perfusion. 
Once the basal neurochemical levels (i.e., HPLC peaks) became constant, a BAS Uniswitch® 
Syringe Selector switched the perfusion solution to aCSF containing 10.0 mM MPTP for 30 min, after 
which the perfusate was switched back to aCSF. Microdialysate samples were then monitored for the 
next 4 to 5 h. 
 
9.  Calculations and Statistics 
Analyte concentrations measured in in vivo microdialysis samples were expressed as nM ± 
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SEM (or percentage of basal level ± SEM) based on at least three replicate experiments.  The effects 
of MPTP on neurochemical levels compared concentrations measured before, during and after 
perfusion using one-way ANOVA. A p-value < 0.05 was taken as significant. Origin™ (version 6.0, 
Microcal Software Inc.; Northampton, MA) was used for plots and statistical calculations. 
 
C. Results and Discussion 
1. Parent Ions, Daughter Ions and CID Optimization for All Analytes. 
Parent ions information was obtained from MS full scan spectra. Daughter ions and CID 
optimization were achieved by CID with energy-step-increase experiments.  
 
Figure 4- 1. Mass spectrum of 5-HT. 
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Figure 4- 2. MS/MS spectrum of 5-HT (177.1). 
 
 
Figure 4- 3. CID optimization data processing for 5-HT. 
 71 
10 20 30 40 50
-10
0
10
20
30
40
50
60
70
80
90
100
110
120
115
117
132
177
160
 
 
In
te
n
si
ty
 
(ch
ro
m
to
gr
a
ph
y 
pe
a
k 
a
re
as
 
x1
06
)
Collision Energy (volt)
 
Figure 4- 4. CID breakdown curve for 5-HT. 
 
Figures 4-1 through 4-4 illustrate how CID optimization was performed for 5-HT. Parent ion 
(177 m/z) and major daughter ions (160, 132, 117, 115 m/z) information was obtained from the MS 
full scan and MS/MS spectra, respectively.  Extracted Ion Chromatography (EIC) for the parent ion 
and major daughter ions were established and are presented in Figure 4-3. A plot of their peak areas 
versus collision energy is shown in Figure 4-4; this is also known as the CID breakdown curve. Thus, 
from this curve it is clear that the best CID condition was ~16 eV for the daughter ion of 160 m/z.  
Thus the optimized SRM condition for 5-HT is 177.1→160.1@16eV.   
Figures 4-5 − 4-16 show spectra and CID breakdown curves for each of the other four 
analytes. The optimized SRM conditions are summarized in Table 4-1. 
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Figure 4- 5. Mass spectrum of DA 
 
 
Figure 4- 6. MS/MS spectrum of DA 
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Figure 4- 7. CID breakdown curve for DA 
 
 
Figure 4- 8. Mass spectrum of EPI. 
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Figure 4- 9. MS/MS spectrum of EPI. 
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Figure 4- 10. CID breakdown curve for EPI. 
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Figure 4- 11. Mass spectrum of 3-MT. 
 
Figure 4- 12. MS/MS spectrum of 3-MT. 
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Figure 4- 13. CID breakdown curve for 3-MT. 
 
 
Figure 4- 14. Mass spectrum of NE 
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Figure 4- 15. MS/MS spectrum of NE 
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Figure 4- 16. CID breakdown curve for NE. 
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Substance SRM optimized conditions 
3-MT 168.1→151.1@16eV. 
5-HT 177.1→160.1@16eV. 
DA 154.1→137.1@16eV. 
EPI 184.1→166.1@16eV. 
NE 170.1→152.1@13eV. 
Table 4- 1. Optimized SRM conditions for all analytes 
 
2. Influence of Different MS Scan Modes on the HPLC-MS S/N. 
Figure 4- 17. MS scan mode influence on S/N ratio in HPLC-MS. 
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In Figure 4-17, the signal to noise (SN) ratio increased one order of magnitude when the SIM 
scan mode was compared to the full scan mode, and another order of magnitude enhancement was 
achieved when the SRM scan mode was employed. This illustrates the reason that the SRM approach 
is more and more popular and becomes the method of choice for HPLC-MS analysis of biological 
samples.  
Still in Figure 4-17, a comparison of the DA HPLC peak areas (noted as MA) for three 
different scan modes reveals that they are opposite to the trend for the S/N ratio. The increase of the 
S/N ratio is due totally to decreasing noise. This reveals a fundamental mechanism to enhance the S/N 
ratio by employing a different scan mode: SIM or SRM did not increase the signal intensity, but 
selectively decreased the noise intensity. This unique capability is a huge advantage for MS compared 
to other commonly used detection techniques.   
 
3. Standard Curves and Sensitivity. 
 
 
Table 4- 2.  Calibration curves, limit of detection (LOD) and linear dynamic range. 
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Calibration information is summarized in Table 4-2. SRM is a very specific detection 
technique and matrix interference with the analyte signal is minimized. Thus, not only were better  
LOD values (compared to full scan or SIM scan MS) achieved, but also better correlation coefficients 
and wider linear dynamic ranges were obtained routinely.   
 
4. In Vitro Experiments 
Microdialysis probe recovery values obtained from in vitro experiments are summarized in 
Table 4-3. 
 
 
Table 4- 3.  In vitro microdialysis probe recoveries for all analytes at different concentrations. 
 
5. In Vivo Experiments.  
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Figure 4- 18. Typical data for in vitro examination. 
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Figure 4- 19. Typical data after aCSF wash and before probe implantation. 
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Figure 4- 20. Typical data for microdialysate basal neurochemical levels (EPI not detected). 
 
 
Figure 4- 21. Typical data for microdialysate neurochemical levels after drug perfusion 
(EPI not detected). 
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Figures 4-18 to 4-21 show representative neurochemical levels observed in in vitro 
experiments, aCSF wash solutions, in vivo basal, and in vivo post-drug measurement.  
The following table lists basal microdialysate levels of the targeted neurochemicals measured 
in vivo. 
 
Substance Basal level in dialysate (mean ± SEM, n=3) /nM 
3-MT 3.5±0.4 
5-HT 4.3±2.1 
DA 6.4±0.7 
EPI Not detected 
NE 0.8±0.2 
Table 4- 4.  Basal microdialysate levels of targeted neurochemicals. 
 
The following figures present microdialysate concentration-time profiles for NE, DA, 3-MT 
and 5-HT detected in in vivo experiments.  
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Figure 4- 22. Time-dependent effects of a 30-min perfusion of 10 mM MPTP into the rat 
striatum on microdialysate levels of DA. The horizontal black bar shows the time during 
which MPTP was perfused. Data are mean ± SEM (bars) percentages of basal DA levels 
(n=3). * p < 0.05, ** p < 0.01. 
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Figure 4- 23. Time-dependent effects of a 30-min perfusion of 10 mM MPTP into rat striatum on 
microdialysate levels of 3-MT. The horizontal black bar shows the time during which MPTP was 
perfused. Data are mean ± SEM (bars) percentages of basal 3-MT levels (n=3). * p < 0.05, ** p < 
0.01. 
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Figure 4- 24. Time-dependent effects of a 30-min perfusion of 10 mM MPTP into rat striatum on 
microdialysate levels of 5-HT. The horizontal black bar shows the time during which MPTP was 
perfused. Data are mean±SEM (bars) percentages of basal 5-HT levels (n=3). * p < 0.05, ** p < 
0.01. 
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Figure 4- 25. Time-dependent effects of a 30-min perfusion of 10 mM MPTP into rat striatum on 
microdialysate levels of NE. The horizontal black bar shows the time during which MPTP was 
perfused. Data are mean ± SEM (bars) percentages of basal NE levels (n=3). (* p<0.05, ** 
p<0.01, # virtually undetectable). 
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Probe insertion caused extracellular levels of all four detected analytes to increase significantly. 
Subsequently, all analytes rapidly declined to basal levels in 30 min. Perfusion of 10 mM MPTP 
dissolved in aCSF evoked an almost immediate and significant release of DA, 5-HT and NE. The 
massive release of all three analytes reached peak values at ca. 40 min. The peak value for DA was 
20,000%, 5-HT was 1,700% and NE was 1,600% above basal levels. After reaching peak levels, 
extracellular concentrations of DA and 5-HT declined rapidly (100-120 min) to basal levels, whereas 
the decline of NE was much slower (180 min). The concentration-time profile for 3-MT was different 
from the other analytes. Thus, there was a 20-min delay before microdialysate levels of 3-MT began to 
increase upon MPTP perfusion. The massive release of 3-MT reached a peak value of 6,000% above 
basal level after 60 min, remained at this peak value for another 60 min, and then declined slowly to 
basal level after 240 min. Compared to the previous studies done in our lab170,190 and other 
researchers,191 where electrochemical detection was employed, the basal dialysate concentrations are 
very close and the concentration profiles are also similar. However, HPLC-MS has advantages over 
other detection methods because it usually gives unequivocal evidence for the identity of analytes. 
D. Conclusions 
In this chapter, the fully automated system was employed to monitor in vivo three 
catecholamines (DA, NE and EPI), 5-HT and 3-MT. The SRM conditions for all analytes were 
optimized by off-line experiments. The fully automated system was extensively used to prepare 
calibration curves, determine in vitro microdialysis probe recoveries, and in connection with in vivo 
experiments. These studies established that the system was a powerful tool for real-time, highly 
sensitive and specific measurement of multiple metabolites in a living animal. 
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Chapter Five 
 
Fully Automated On-line Sample Cleanup and HPLC-MS/MS 
Determination of GSH and CySH in Rat Brain Striatum: An In 
Vivo Microdialysis Study. 
 
A. Introduction 
GSH and CySH are ubiquitous thiol-containing molecules in organisms. GSH and CySH play 
a central role in cell biology, especially cellular protection against various toxic compounds such as 
free radicals and hydroperoxides.192,193 GSH and CySH status is a highly sensitive indicator of cell 
functionality.194  
 Numerous analytical approaches have been established to determine GSH and CySH in 
biological samples. Among them, capillary electrophoresis coupled with UV195-199 or fluorimetric 
detection,200 and HPLC coupled with UV200-204 or electrochemical detection205-207 have been 
frequently employed. In addition, NMR spectroscopy has been utilized for analysis of intact cells for 
GSH and CySH.208 However, direct GSH and CySH analyses without derivatization are rare. The 
purposes of derivatization are to prevent autoxidation of GSH and CySH, to improve chromatographic 
retention, or to enhance sensitivity. HPLC-MS is a highly specific and sensitive technique, and has 
been applied to the analysis of blood cell and liver GSH content. However, the available methods are 
time consuming because of sample preparation procedures such as liquid-liquid extraction and off-line 
derivatization.151,209-211 Fully automated HPLC-MS analyses of GSH and CySH in microdialysate 
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samples have not been previously reported.  
In this chapter, a fully automated system is described which combines microdialysis sampling, 
on-line derivatization (Figures 5-1 and 5-2), on-line IP-RP-SPE sample clean-up, IP-RP-HPLC 
separation and tandem MS/MS detection techniques to monitor GSH and CySH in the striatum of rats 
in response to perfusion of the parkinsonian toxins MPTP and MPP+. 
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Figure 5- 1. Derivatization reaction for GSH. 
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Figure 5- 2. Derivatization reaction for CySH. 
 
B. Experimental 
1. Chemicals and Chromatographic Conditions. 
Most of the chemicals used and chromatographic conditions were the same as described in 
Chapters Two and Three. EZ-Link® Maleimide polyethyleneoxide, 2 (PEO2)-Biotin (MPB; structure 
shown in Figures 5-1 and 5-2) was purchased from Pierce Inc (Rockford, IL). Upon arrival, the MPB 
was weighed and distributed into smaller portions (0.6-1.2 mg each) and stored in securely capped 
plastic vials.  The vials were stored in a dessiccator at ~4oC. MPB solution was always freshly 
prepared before experiment. Upon usage, the calculated amount of water was added to the above vials 
to obtain MPB at the desired concentrations. All of the above approaches were employed to protect the 
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moisture-sensitive MPB from hydrolysis and loss of function.   
2. Instrumentation. 
 On-line derivatization was carried out by adding a 3-way micro-mixer to the fully automated 
system described in Chapter Two. An overview of the modified system is presented in Figure 5-3.  
 
 
Figure 5- 3. Overview of the modified fully automated system 
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The additional syringe B was a Hamilton gastight® 250 µL syringe (1700 series; VWR 
Scientific, West Chester, PA). It had the same effective length (6.0 cm) as syringe A. Thus the actual 
output flow rate from syringe B was 0.375 µL/min. This syringe was filled with 5.0 mM MPB in water. 
The solution was thoroughly degassed (He sparging) prior to use. After mixing with dialysate, which 
was driven by syringe A, the MPB was automatic diluted (1 : 4) to a concentration of 1.0 mM in the 
perfusate solution.  
The on-line micro-mixer was a homemade device using a modified CMA 12® microdialysis 
probe (Figure 5-4). Thus, the probe membrane was removed and the inlet needle tubing was cut to the 
level of the end of the shield tubing. During experiments the microdialysate solution coming from the 
rat brain was connected to the original inlet of the probe. The inlet and the inlet needle has a very 
small dead volume (<1 µL) so that chromatographic resolution was not compromised. The MPB 
solution was connected to the original outlet of the probe and flowed out through the shield tubing. 
The outlet and the shield tubing had a larger dead volume (~3 µL), but it does not matter for the 
homogenous MPB solution. In such a setting, the MPB solution appears as a sheath solution to the 
microdialysate. (Figure 5-4)  The microdialysate and MPB solutions mix together at the end point of 
the shield tubing and continue mixing as they are pumped into the sample loop. The derivatization 
reactions (Figures 5-1 and 5-2) occur in room temperature when these solutions are mixed. The 
advantages of this on-line mixer include very low dead volume, easy connection using microdialysis 
tubing and adapters, and low cost. 
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Figure 5- 4. Structure of microdialysis probe and its modification to be as a micro-mixer. 
 
3. Stock and Standard Solutions. 
Stock standard solutions of GSH and CySH (10 mM) were prepared and stored as described in 
Chapter Two.  GSH-MPB and CySH-MPB stock standard solutions (1 mM, stoichiometric 
calculated by assuming a 100% yield for the derivatization reactions) used to optimize SRM 
conditions were prepared as follows: 25 µL 10 mM GSH/CySH stock standard solution and 25 µL 20 
mM MPB solution were added to 200 µL aCSF solution in a plastic vial. The vial was left in room 
temperature for 1h to complete the reaction, then stored at ~ 4oC for later use. 
GSH-MPB/CySH-MPB standard solution (10 µM each) was prepared by adding 10 µL 
GSH-MPB/CySH-MPB stock standards (1 mM) to 990 µL aCSF. 
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Standard solution for GSH/CySH (10 µM) was prepared as follows: 10 µL of 10 mM 
individual stock solutions were added to 990 µL aCSF to obtain a 100 µM solution; 100 µL of such 
solution was added to 900 µL aCSF to obtain the 10 µM solution. 
A series of calibration standard mixture solution (50 µM, 20 µM, 10 µM, 5 µM, 2 µM, 1 µM, 
0.5 µM and 0.2 µM) were prepared as follows: 10 µL of 10 mM stock standard solutions of GSH and 
CySH were added to 980 µL aCSF to obtain a 100 µM mixed standard solution; 500 µL of this 
solution was added to 500 µL aCSF to obtain a 50 µM solution; 400 µL of  the 50 µM solution was 
added to 600 µL aCSF to obtain a 20 µM solution; 200 µL of 20 µM solution was added to 600 µL 
aCSF to obtain a 5 µM solution; 400 µL of 5 µM solution was added to 600 µL aCSF to obtain 2 µM 
solution; 500 µL of 2 µM solution was added to 500 µL aCSF to obtain 1 µM solution; 500 µL of 1 
µM solution was added to 500 µL aCSF to obtain 0.5 µM solution; 400 µL of 0.5 µM solution was 
added to 600 µL aCSF to obtain 0.2 µM solution. All solutions were stored in plastic vials on ice in a 
covered container and were passed through 0.2 µm centrifuge filter before use.   
The standard mixture solutions (40 µΜ, 10 µM, 5 µM and 2 µM) for in vitro experiments were 
prepared in a similar manner to that described above. 
 
4. Selected Reaction Monitoring (SRM) Optimization.  
 SRM optimization was carried out in the same way described in Chapter Four except that 10 
µM GSH, CySH, GSH-MPB and CySH-MPB standard solutions were used. 
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5. Calibration Curves  
Calibration curves were determined in the same way described in Chapter Four except that a 
series of GSH and CySH standard mixture solutions were used and the modified fully automated 
system describe earlier in this chapter was employed. 
 
6.  In Vitro Microdialysis Experiments 
The procedure for in vitro microdialysis experiments was the same as described in Chapter 
Four, except that 2 µM, 5 µM, 10 µM and 40 µM mixed GSH and CySH standard solutions were used 
and the modified fully automated system describe previously in this chapter was employed. 
 
7.  Animals and Surgical Procedures 
Animals and surgical procedures were the same as in Chapter Four.  
 
8. In Vivo Microdialysis (Probe Recovery Studies). 
In vivo microdialysis followed the same protocols described in Chapter Four but with the 
following differences: 1) the modified fully automated system described in this chapter was employed: 
2) a 5 mM MPB in water solution was prepared in the preparation step; 3) a 10 µM GSH and CySH 
standard mixture solution was employed for the in vitro studies (probe recoveries); and, 4) 10 mM 
MPTP, 2.5 mM MPP+ and 5 mM MPP+ were perfused into the rat striatum. 
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9.  Calculations and Statistics 
Data calculations and statistics were the same as described in Chapter Four. 
C. Results and Discussion 
1. Parent Ions, Daughter Ions and CID Optimization for GSH, CySH, 
GSH-MPB and CySH-MPB. 
Parent ion information was obtained by means of MS full scan spectra; daughter ion 
information and CID optimization were achieved using CID energy-step-increase experiments. The 
data processing technique for CID breakdown curve establishment was described in Chapter Four. 
Figures 5-5 − 5-16 present spectra and CID breakdown curves for each of the four analytes. 
The optimized SRM conditions are summarized in Table 5-1. 
 
Figure 5- 5. Mass spectrum of CySH. 
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Figure 5- 6. MS/MS spectrum for CySH. 
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Figure 5- 7. CID breakdown curve for CySH 
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Figure 5- 8. Mass spectrum of GSH. 
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Figure 5- 9. MS/MS spectrum for GSH. 
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Figure 5- 10. CID breakdown curves for GSH. 
 
Figure 5- 11. Mass spectrum of GSH-MPB. 
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Figure 5- 12. MS/MS spectrum for GSH-MPB. 
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Figure 5- 13. CID breakdown curves for GSH-MPB. 
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Figure 5- 14. Mass spectrum of CySH-MPB. 
 
Figure 5- 15. MS/MS spectrum for CySH-MPB. 
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Figure 5- 16. CID breakdown curves for CySH-MPB. 
 
Substance SRM optimized conditions 
GSH 308.1 → 179.1 @ 17 eV 
CySH 122.1 →76.1 @ 19 eV 
GSH-MPB 833.3 → 704.3 @ 30 eV 
CySH-MPB 647.2 → 629.2 @ 25 eV* 
Table 5- 1. SRM optimized conditions for all analytes. 
* Not obtained from graph; discussed further later in this chapter. 
 
2. Pre-Column Derivatization: Why It Was Necessary? 
As discussed in Chapter Three, the primary reason for pre-column derivatization was that GSH 
and CySH were literally not retained on the SPE column. Another reason was that CySH displayed 
very poor chromatographic behavior on the HPLC column we used. The following Figure compares 
the chromatographic behavior of CySH and GSH.  
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Figure 5- 17. GSH and CySH standard, SPE wash time: 0.2 min. 
 
As illustrated in Figure 5-17, GSH exhibited much better chromatographic behavior.  Thus, 
the retention time was longer (3.25 min vs. 2.48 min for CySH.), and the peak shape was much better 
(FWHM: 0.08 min vs. 0.4 min). It is worth noting that a very short SPE wash time (0.2 min) was 
employed for the above experiment in order to obtain any signals for GSH and CySH. Such a short 
SPE wash time was deemed unacceptable because they actually co-eluted from SPE column with salts 
in aCSF.  
However, when the sample pH was decreased (by adding formic acid), the detection of GSH 
drastically improved, as illustrated in Figure 5-18. Also note that for this experiment a longer SPE 
wash time (0.5 min) SPE was used. 
Thus, no signal was detected for GSH at pH 6 (Figure 5-18, lower trace). A weak peak 
appeared when the pH was decreased to 3 and the signal intensified further as the pH was decreased 
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further.  Lower pH values than 1 were not studied because under such conditions the SPE column 
can be damaged or destroyed. Nonetheless, acidification did not improve CySH detection (data not 
shown).   
 
Figure 5- 18.  1µM GSH standard at different pH values; the SPE wash time was 0.5 min. 
 
The conclusion from the preceding experiments was that GSH can be analyzed without on-line 
derivatization although on-line acidification was necessary. On the other hand, for CySH analysis, 
on-line derivatization seemed inevitable for utilizing the fully automated system. Following on-line 
derivatization, the derivatization products, GSH-MPB and CySH-MPB, exhibited very good 
chromatographic behaviors (Figure 5-19). 
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Figure 5- 19. 10 µM GSH and CySH mixture in aCSF solution with on-line derivatization 
(resulted in GSH-MPB and CySH-MPB) and a SPE wash time of 1.0 min. 
 
3. Standard Curves and Limits of Detection (LOD). 
 
Table 5- 2.  Calibration, LOD and linear dynamic range for GSH and CySH. 
 
4. Derivatization – “to be or not to be, that is the question”. 
The main purpose for derivatization was to improve GSH and CySH retention on the SPE 
column such that interfering substances like salts were washed away in the SPE step. The dilemma was 
that the derivatization process necessarily introduces a new interferent, unreacted MPB. A huge excess 
of MPB (concentration ~3 orders of magnitude higher than the analytes) was employed to facilitate the 
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derivatization reaction. Unfortunately, the on-line SPE process was unable to eliminate unreacted MPB, 
as illustrated in Figures 5-20 and 5-21. 
 
Figure 5- 20. aCSF blank solution, on-line-SPE-HPLC-MS in full scan mode. 
 
 
Figure 5- 21. MPB in aCSF, on-line-SPE-HPLC-MS in full scan mode. 
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Comparing Figures 5-20 and 5-21, the use of MPB caused tremendous contamination. In the 
TIC chromatogram in Figure 5-21, many pollutant peaks appeared between 9−11 min. The chemical 
identity of these contaminants, except unreacted MPB, was hard to determine. The EIC chromatogram 
of MPB (526 m/z) itself indicated a giant peak (huge peak area) with a retention time of 9.39 min, 
which appeared distinct from the peaks for both GSH-MPB (~7.5 min) and CySH-MPB (~10.3 min). 
Thus, unreacted MPB itself does not directly affect the analysis of GSH and CySH. However, the 
unknown impurities of MPB could caused significant interference. EICs with the same m/z values as 
the parent ions for GSH-MPB (833) and CySH-MPB(647) are displayed in Figure 5-21, lower two 
traces. The 833 m/z interfering peak (~9.9 min) appears far away from the GSH-MPB peak at ~7.5 
min, meaning GSH analysis should not be affected. Unfortunately, there was a significant 647 m/z 
HPLC peak close to the CySH-MPB retention time (10.3-10.5 min).  
 
Figure 5- 22.  MPB in aCSF, on-line-SPE-HPLC-MS in SRM scan mode. 
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If the daughter ion pattern for the interferent at 647 m/z are different from those of CySH-MPB, 
they would not interfere with the determination of the latter derivative using the SRM technique.  
However, Figure 5-22 illustrates how the 647 m/z ion from MPB solution in fact interfered the 
analysis of CySH-MPB. In this experiment, MPB in aCSF solution was used, three reactions were 
monitored simultaneously: 647→270@42eV, 647→375@32eV, 647→629@25eV. These reactions 
were three best reactions for SRM analysis of CySH-MPB derived in Figure 5-16. In Figure 5-22, the 
first two reactions have significant HPLC peaks close to the CySH-MPB peak (not shown), which 
would severely affect the analysis of CySH. However, the third reaction appeared free from 
interference. Thus, the reaction 647→629@25eV became the optimized SRM condition for CySH 
analysis (Table 5-1). It should be pointed out that this reaction had a much lower sensitivity compared 
to the other two reactions, especially to 647→270@42eV (peak intensity: 1.0 × 106 vs. 6.8 × 106, 
Figure 5-16). Thus, the interference accompanied with derivatization procedure causes lower 
sensitivity for CySH detection. That was a price paid for derivatization analysis. 
As stated previously, determination of the chemical structure of the interferent (647 m/z) in 
the MPB solution is virtually impossible. However, MS technique provided an opportunity to 
investigate the interferent which has the same parent ion (647 m/z), the same daughter ions (270 and 
375) and the same retention time (~10.4 min) as CySH-MPB. Figure 5-23 is full scan (100-900 m/z) 
mass spectrum of all the compounds in the MPB/aCSF solution that eluted at retention times ranging 
from 10.3 to 10.5 min in Figure 5-21.  
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Figure 5- 23.  Full scan mass spectrum between retention times 10.3 to 10.5 min of MPB in 
aCSF solution. 
 
All of the ions shown in Figure 5-23 co-eluted with CySH-MPB, for they have identical 
retention times. Nonetheless, for SRM analysis only one ion survived after the first quadrupole 
filtering, which is the ion of 647.3 m/z (parent ion for CySH-MPB). The actual procedure to do this 
was to set up a small window which has a width of 1.0 m/z centered at 647.3 m/z. Then this small 
window was applied to the first quadrupole, so only this ion was passed through. The embedded 
spectrum in Figure 5-23 shows the detailed mass spectrum of the ions (647.3 m/z) and surrounding 
ions.  The series 646.3, 647.3 and 648.3 peaks apparently fit an isotopic pattern for a typical organic 
molecule. Thus, the ion of 647.3 m/z, which originated from MPB aCSF solution, is actually the 
isotopic ion of 646.3 m/z. This ion was resulted from the less abundant naturally occurred isotopes 13C, 
2H, 15N etc. in the 646.3 compound. The chemical structure of the interferent ion, at 646.3 m/z, could 
be further elucidated by measuring its accurate m/z value, the relative abundances of all isotopic peaks 
and MS/MS spectrum. Nonetheless this was beyond the scope of this research project. 
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This is an example of how MS, as sensitive as it is, is vulnerable to minute impurities in the 
sample. It also raised the question of whether derivatization should be employed, since the 
impairments caused by a huge excess of the derivatization reagent with all kinds of unknown 
impurities might be much greater than endogenous matrix compounds in microdialysates like salts. 
Indeed, it is a widely-held opinion that derivatization should always be treated as a last resort in 
HPLC-MS method development. When derivatization must be employed, great caution should be 
taken concerning the reagent purity and possible side reactions. In this research project, it was 
concluded that CySH has to be derivatized, although at the expense of decreased sensitivity and much 
more frequent mass spectrometer maintenance, i.e., from every 3 month to every 2 weeks, in order to 
maintain sensitivity.  
 
5.  In Vitro Microdialysis (Probe Recovery Studies). 
 
 
Figure 5- 24. Typical data for in vitro experiments. 
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Table 5- 3.  Probe recoveries for GSH and CySH. 
 
6. In Vivo Experiments.  
The following are the results obtained from in vivo experiments. 
 
Figure 5- 25. Typical data for in vivo experiments, including necessary in vitro checkup 
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Figure 5- 26. Time-dependent effects of a 30-min perfusion of 2.5 mM MPP+ into rat striatum 
on microdialysate levels of GSH and CySH. The horizontal black bar shows the time during 
which MPP+ (dissolved in aCSF) was perfused. Data are percentages of basal GSH and CySH 
levels 
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Figure 5- 27. Time-dependent effects of a 30-min perfusion of 5mM MPP+ into rat striatum on 
microdialysate levels of GSH and CySH. The horizontal black bar shows the time during which 
MPP+ (dissolved in aCSF) was perfused. Data are mean ± SEM bars) percentages of basal GSH 
and CySH levels (n = 3). * p < 0.05, ** p < 0.01. 
 112 
The basal concentration for GSH was 0.6 ± 0.1 µM (mean ± SEM, n=3) in microdialysate 
samples and for CySH was 6.2 ± 0.4 µM (mean ± SEM, n=3). The probe insertion caused extracellular 
(microdialysate) concentrations of both GSH and CySH to increase significantly (Figure 5-27), and 
then both declined rapidly to basal levels. In preliminary experiments, perfusions of 10 mM MPTP in 
aCSF solution failed to evoke any increase in microdialysate levels of GSH or CySH (data not shown). 
Accordingly, the effects of its metabolite MPP+ were studied. In preliminary experiment, the 
concentration of MPP+ employed was 2.5 mM and the effect of MPP+ on GSH and CySH was so 
small that it was decided not to waste additional animals. Accordingly, in subsequent experiments, a 
MPP+ concentration of 5 mM was employed. In experiments using 5 mM MPP+ (Figure 5-27), during 
perfusions extracellular concentrations of GSH and CySH were not significantly different from basal 
levels. However, when MPP+ perfusions were discontinued, extracellular GSH increased massively, 
reaching 650% (60 min) of basal levels, and then declined to basal level in about 90 min. After 
discontinuing MPP+ perfusion, CySH continued to increase but more slowly and peaked later than that 
GSH at 1,100% (180 min) above basal level. Subsequently, extracellular CySH slowly declined, 
although remaining significantly above basal level until the end of the experiment (270 min).  
The extracellular GSH and CySH profiles reported above are in approximate agreement with 
previously results from our laboratory when HPLC-EC was employed to monitor levels of these thiols 
in microdialysate samples.207  However, the maximum increase of GSH was much higher previously 
(5,000% vs. 650%), whereas the CySH peak values were very similar (1,540% vs. 1,100%). It is 
worth pointing out that HPLC-MS/MS (SRM) is a much more specific technique than HPLC-EC. 
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D. Conclusions 
In this chapter, the highly specific and sensitive fully automated system combining 
microdialysis sampling, on-line derivatization, on-line IP-RP-SPE sample preparation, IP-RP-HPLC 
separation, and tandem MS/MS detection techniques were applied to monitor GSH and CySH in rat 
striatal microdialysates in response to MPTP or MPP+ perfusion. The conditions for SRM of all 
analytes were optimized using off-line experiments. The fully automated system was extensively used 
in calibration curve, in vitro microdialysis probe recovery, and in vivo experiments. All these 
experiments showed this system to be a powerful tool for real-time, highly specific and sensitive 
monitoring of targeted metabolites in biological systems. 
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Chapter Six 
 
Fully Automated On-line Sample Cleanup and HPLC-MS 
Determination of MPTP Metabolites in Rat Brain Striatum: An In 
Vivo Microdialysis Study. 
 
A. Introduction 
1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) is considered by many neuroscientists 
to hold the key to understanding the pathogenesis of idiopathic PD. The history of MPTP as an animal 
model for PD was described previously. However, the detailed mechanism of MPTP–mediated 
dopaminergic nerotoxicity has yet to be fully established.212,213 Nevertheless, it has been well 
established that MPTP exerts its selective neurotoxic effects through its active metabolite MPP+.214-218 
Direct measurement of MPTP and its metabolites in the brains of animal models of PD should be an 
effective way to help contribute to an understanding of the biological pathway for its selective toxicity 
towards dopaminenergic neurons. The results of such studies, in turn, might thus contribute to an 
understanding of the mechanisms underlying PD. 
Historically, MPTP and its metabolites have been analyzed principally by HPLC-UV215,219-222 
and GC-MS.215,223-225 There have been very few reports of the use of HPLC-MS techniques for such 
analyses although they should, in principal, have great potential.226  The limitations of HPLC-UV 
analyses include its low specificity, since it mainly depends on retention time measurement, and 
susceptibility to many interferences present in biological samples. In the case of GC-MS, the major 
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drawback it that it requires the analytes to be volatile and thermally stable, which was not the case for 
MPTP and its metabolites.  
In this chapter a fully automated system which combines microdialysis sampling, on-line 
IP-RP-SPE sample clean-up, IP-RP-HPLC separation, and selected ions monitoring (SIM) detection 
techniques was employed to monitor MPTP and its metabolites 4-phenyl-1,2,3,6-tetrahydropyridine 
(PTP), 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), 1-methyl-4-phenyl-1,2,3,6- 
tetrahydropyridine- N-Oxide (MPTP-N-Oxide) and (1-methyl-4-phenylpyridinium) MPP+ in rat 
striatal microdialysates in response to perfusion of MPTP.  
  
B. Experimental 
1.  Chemicals and Chromatographic Conditions. 
Chemicals and chromatographic conditions were the same as in Chapters Two and Three.  
 
2.  Instrumentation. 
 The fully automated system used was described in Chapter Two  
 
3.  Stock and Standard Solutions. 
Stock standard solutions for MPTP (10 mM) and MPP+ (5 mM) were prepared and stored as 
described in Chapter Two.   
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Standard solutions for MPTP/MPP+ (10 µM) was prepared as follows: 10 µL of 10 mM 
individual stock solutions were added to 990 µL aCSF to obtain 100 µM solutions; 100 µL of such 
solution was added to 900 µL aCSF to obtain 10 µM solutions. 
A series of calibration standard mixture solutions (2 µΜ, 500 nM, 100 nM, 20 nM, 5 nM, 2 
nM, 1 nM and 0.5 nM) was prepared as follows: 10 µL 10 mM stock standard solution of MTPT and 
MPP+ was added to 980 µL aCSF to obtain 100 µM mixed standard solution; 20 µL of this solution 
was added to 980 µL aCSF to obtain 2 µM solution; 400 µL of 2 µM solution was added to 600 µL 
aCSF to obtain 500 nM solution;  200 µL of 500 nM solution was added to 800 µL aCSF to obtain 
100 nM solution; 200 µL of 100 nM solution was added to 800 µL aCSF to obtain 20 nM solution; 
400 µL of 20 nM solution was added to 600 µL aCSF to obtain 5 nM solution;  400 µL of 5 nM 
solution was added into 600 µL aCSF to obtain 2 nM solution; 500 µL of 2 nM solution was added 
into 500 µL aCSF to obtain 1 nM solution; 500 µL of 1 nM solution was added into 500 µL aCSF to 
obtain 0.5 nM solution; All solutions were stored in plastic vials placed on ice in a covered igloo, and 
were passed through 0.2 µm centrifuge filter before use.   
The standard mixture solutions for in vitro (1 µΜ and 5 µM) experiments were prepared in the 
same manner described above. 
 
4.  Selected Reaction Monitoring (SRM) Optimization.  
 SRM optimization was carried out in the same way described in Chapter Four except that10 
µM MPTP and MPP+ individual standard solutions were injected. 
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5.  Calibration Curves  
The fully automated system describe in Chapter Two was employed to determine calibration 
curves. Detailed procedures are described in Chapter Four except that a series of MPTP and MPP+ 
standard mixture solutions were used. In addition, MS in the SIM scan mode for MPTP (174 m/z) and 
MPP+ (170 m/z) was employed. 
 
6.  In Vitro Microdialysis Experiments 
The fully automated system was employed to perform in vitro microdialysis experiments 
(probe recoveries), the procedures being the same as in Chapter Four except that 1 µM and 5 µM 
mixed MPTP and MPP+ standard solutions were used and the MS SIM scan mode was employed. 
 
7. Animals and Surgical Procedures 
Animals and surgical procedures were the same as described in Chapter Four.  
8. In Vivo Microdialysis. 
In vivo microdialysis followed the same protocols described in Chapter Four with the 
following modifications: a) a 1 µM MPTP and MPP+ standard mixture solution was employed in the 
in vitro studies (probe recovery check); and, b) the MS SIM scan mode was performed at 160 m/z 
(PTP), 170 m/z (MPP+), 172 m/z (MPDP+), 174 m/z (MPTP) and 190 m/z (MPTP-N-Oxide).   
 
9. Calculations and Statistics 
Data calculations and statistics were the same as described in Chapter Four. 
 118 
C. Results and Discussion 
 
1. Parent Ions, Daughter Ions and CID Optimization for MPTP and MPP+. 
Parent ion information was obtained by means of MS full scan spectra. Daughter ion 
information and CID optimization were achieved by CID energy-step-increase experiments. Data 
processing for CID breakdown curve establishment was described in Chapter Four. 
Figure 6-1 and 6-2 present spectra and CID breakdown curves for MPTP and MPP+. The 
optimized SRM conditions are summarized in Table 6-1.  
  
Figure 6- 1. Mass spectrum of MPTP. 
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Figure 6- 2. MS/MS spectrum of MPTP. 
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Figure 6- 3. CID breakdown curves for MPTP. 
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Figure 6- 4.  Mass spectrum of MPP+. 
 
 
 
 
Figure 6- 5. MS/MS spectrum of MPP+. 
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Figure 6- 6. CID breakdown curves for MPP+ 
  
 
Substance SRM optimized conditions 
MPTP 174.1 → 44.1 @ 30 eV 
MPP+ 170.0 →128.0 @ 40 eV 
Table 6- 1. SRM optimized conditions for MPTP and MPP+. 
 
Although SRM is the preferred MS technique on most occasions for biological samples, 
selected ion monitoring (SIM) was employed for the remainder of the experiments described in this 
chapter, including calibration curves, in vitro and in vivo experiments. The reasons were: 1) it was not 
possible to obtain the standards for three targeted MPTP metabolites, i.e. PTP, MPDP+, 
MPTP-N-Oxide; 2) only parent ion information was available in literature sources for the above three 
 122 
metabolites, which could be used for the SIM experiment setup but inadequate for SRM experiments; 
and, 3) the fragmentation pattern for MPTP was not very suitable for SRM, i.e. MPTP has only one 
detectable daughter ion, and its intensity was low (< 20% of the parent ion signal intensity as shown in 
Figure 6-3). The principle disadvantage of the SIM approach is its relatively low specificity compared 
to SRM. Thus it may not appropriate when server interference happens. However, in our experiment, 
the interference was not significant.  
 
2. Standard Curves and Sensitivity. 
Calibration information for MPTP and MPP+ is summarized in the Table 6-2. 
 
 
Table 6- 2. Calibration parameters, LOD and linear dynamic range for MPTP and MPP+. 
 
3. In Vitro Microdialysis and Probe Recovery Measurements. 
Figure 6-7 presents typical data obtained from in vitro experiments. The in vitro standard 
mixture solution used contained 1 µM concentrations of both MPTP and MPP+. Also shown are results 
for aCSF solution (blank). Compared to SRM data reported in previous chapters, SIM was less 
specific, thus there were some interfering peaks at retention times of 1.0 min and 4.8 min for both 
MPTP and MPP+. Nonetheless, no significant interference appeared at the retention time of ~12.5 min 
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where both MPTP and MPP+ eluted. The peaks for MPTP and MPP+ were almost overlapped in TIC 
(not shown), however they were separated in EIC chromatograms. Table 6-3 summarizes 
microdialysis probe recovery data. 
 
 
Figure 6- 7. Typical data from in vitro (probe recovery) experiments. 
 
 
 
 
Table 6- 3. Probe recoveries for MPTP and MPP+ 
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4. In Vivo Experiments.  
During in vivo experiments, five ions were monitored at m/z = 160 (PTP), 170 (MPP+), 172 
(MPDP+), 174 (MPTP), and 190 (MPTP-N-Oxide). In order to protect the MS detector, MPTP was not 
monitored until 30 min after the perfusion finished. The following figures present the results obtained 
from in vivo experiments. 
 
 
 
Figure 6- 8. Typical aCSF blank data (before probe implanted in rat brain). 
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Figure 6- 9. Typical data from in vivo experiments: 100 min after MPTP perfusion was 
terminated. 
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Figure 6- 10. Time-dependent effects of a 30-min perfusion of 10mM MPTP into rat striatum on 
microdialysate levels of MPTP and MPP+. The horizontal black bar shows the time during 
which MPTP was perfused. Data are mean ± SEM (n = 3). * p < 0.05, ** p < 0.01. 
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Figure 6- 11. Time-dependent effects of a 30-min perfusion of 10mM MPTP into rat striatum on 
microdialysate levels of putative MPDP+. The horizontal black bar shows the time during which 
MPTP was perfused. Data are mean ± SEM (n = 3). * p < 0.05, ** p < 0.01. 
 
In in vivo experiments, PTP chromatograms did not show any significant peaks throughout 
the experiment (data not shown). MPTP-N-Oxide chromatography peaks did not change significantly 
throughout the experiment.  During 10 mM MPTP perfusion, extracellular concentrations of MPP+ 
and MPDP remained very low. However, when MPTP perfusions were discontinued, extracellular 
MPP+ and MPDP+ increased significantly, MPDP+ rapidly reaching a peak value at 60 min and 
remained at this peak value for about 40 min, then declined rapidly over the next 90 min. MPP+ 
increased less rapidly than MPDP+ by reaching the peak concentrations of 500 nM at 100 min, then 
slowly declined.  
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D. Conclusions 
In this chapter, a highly specific and sensitive fully automated system combining 
microdialysis sampling, on-line derivatization, on-line IP-RP-SPE sample clean-up, IP-RP-HPLC 
separation, and tandem MS/MS detection techniques was applied to monitor MPTP and its metabolites 
in rat striatal microdialysates in response to perfusions of 10 mM MPTP. In order to monitor as many 
as possible metabolites, the MS SIM scan mode was employed. The fully automated system was 
extensively used for determination of calibration curves, in vitro microdialysis probe recovery, and for 
in vivo experiments. All these experiments showed this system to be a powerful tool for real-time, 
highly specific and sensitive monitoring of targeted metabolites in biological systems.  
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Chapter Seven 
 
Determination of Arachidonic Acid Metabolites in Rat Striatal 
Microdialysates by HPLC-MS/MS Utilizing Electron Capture 
Atmospheric Pressure Chemical Ionization. 
 
A. Introduction 
Chronic inflammation is becoming increasingly recognized as an important participant in 
numerous neurodegenerative diseases including Alzheimer’s227-229 and Parkinson’s diseases.230,231 
Among the participants in the inflammatory process, the eicosanoids have received substantial 
attention. Eicosanoids originate from the enzymatic oxidation of arachidonic acid (AA) to produce 
proinflammatory prostaglandins, leukotrienes, thromboxanes and alcohols (Figure 7-1).232-237 Accurate 
measurement of trace amounts of AA metabolites in brain may be an important step in understanding 
a role for these eicosanoids in neurodegenerative brain disorders. This is a considerable analytical 
challenge because of their low abundances (concentrations range from picomolar to nanomolar) in 
very complex biological backgrounds, and their isomeric properties (enantiomer, regioisomer and 
stereoisomer). Traditional methods of analysis for eicosanoids have employed HPLC coupled with 
UV238-241, fluorescence242-244 or ESI-MS245-247 detection, GC-MS248-250 and radioimmunoassay.251-253  
These methods suffer from inadequate detection limits, time-consuming sample preparation, inability 
to differentiate isomers, sample instability and cross reactivity. Recently, HPLC-MS/MS with electron 
capture atmospheric pressure chemical ionization (ECAPCI) has been demonstrated to be a promising 
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approach to analyze eicosanoids.254,255  In the present study a modified form of this method was 
employed to analyze several eicosanoids in rat brain striatal microdialysates. Three eicosanoids – 
prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), and prostaglandin F2α (PGF2α) were successfully 
detected in microdialysate samples and both PGE2, and PGF2a were measured quantitatively and 
routinely. The recent use of arachidonic acid-d8 (AA-d8) as an internal standard has greatly increased 
confidence in the quantification process. By this analytical method, the LOD for PGE2 and PGF2α has 
been determined to be 0.1 nM, which is close to the LOD with radioimmunoassay, which is one of the 
most sensitive methods for eicosanoids analysis nowadays. 
The difference between regular APCI and ECAPCI is that the analytes in ECAPCI undergo 
derivatization to tag them with an electron-capturing group such as the pentafluorobenzyl moiety 
before analysis. The pentafluorobenzyl derivatives undergo dissociative electron capture in the gas 
phase to generate negative ions through the loss of pentafluorobenzyl radicals. ECAPCI can provide 
an increase in sensitivity of 2 orders of magnitude when compared to regular APCI.255 Figure 7-2 
illustrates the whole ECAPCI scheme, where PGE2 is the model compound.  
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Figure 7- 1. Eicosanoid cascade and biological pathways: Cyclooxygenase pathway (red), 
lipoxygenase pathway (blue) and non-enzymatic pathway (green). 
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Figure 7- 2. Mechanism for ECAPCI analysis of PGE2.  (a) Esterfication reaction, introducing 
an electron capture tag (PFB moiety).  (b) The production of low energy electron.  (c) Electron 
capture dissociation. 
 
B. Experimental 
1. Reagents and Chemicals. 
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Most chemicals used were the same as in Chapters Two and Three. AA, deuterated AA 
(AA-d8), PGE2, PGD2, and PGF2α were purchased from Cayman Chemical, Inc. (Ann Arbor, MI). 
Butyl hydroxytoluene (BHT), diethyl ether, pentafluorobenzyl bromide (PFB) and 
diisopropylethylamine (DIPE) were obtained from Sigma-Aldrich. PFB was diluted in toluene (1 : 19; 
v/v). DIPE was also diluted in toluene (1 : 9; v/v). HPLC grade toluene, hexanes and isopropanol were 
purchased from Fisher Scientific.  
 
2.  Stock and Standard Solutions. 
AA was provided as 100 µg/µL in ethanol solution. 10 µL of this solution was diluted in 990 
µL of deoxygenated (He sparging) ethanol to obtain a 1 µg/µL solution. 100 µL of the latter solution 
was added to 900 µL deoxygenated ethanol to obtain a 100 ng/µL (~330 µM) solution which was 
stored below -20oC. 
PGE2 and PGD2 were provided as 1 mg solid samples contained in small glass vials with an 
open top septum cap. One mL of deoxygenated ethanol was added to each vial by syringe through the 
septum. The resulting solutions were shaken for several minutes to dissolve the solids to give a 
concentration of 1 µg/µL. 100 µL of such solutions was added to 900 µL of deoxygenated ethanol to 
obtain 100 ng/µL (~280 µM ) solutions which were stored in a freezer at below -20oC. 
PGF2a was provided as a100 ng/µL ethanol solution and stored below -20oC.  
100 µL of each of the above four 100 ng/µL solutions was added to 600 µL of deoxygenated 
ethanol to obtain the standard mixture solution which had a concentration of 10 ng/µL for each of the 
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analytes. This solution was stored at -20oC or lower until needed. 
AA-d8 was provided as a100 ng/µL solution in ethanol. 10 µL of this solution was diluted in 
990 µL of deoxygenated ethanol to obtain a 1 ng/µL solution. 20 µL of this solution was added to 980 
µL of deoxygenated ethanol to obtain a 20 pg/µL solution which was stored at -20oC or lower. 
 
3.  Equipment and Chromatographic Conditions  
HPLC-APCI-MS/MS was performed with a Thermo Finnigan TSQ 7000 equipped with a 
Thermal Finnigan Surveyor® MS pump. A Thermo Hypersil® Silica (250 × 4.6 mm, 5 µm) 
normal-phase HPLC column from Thermo-Hypersil-Keystone (Bellefonte, PA) was used for all 
separations. The mobile phase was isocratic hexanes (90%, v/v) / isopropanol (10%, v/v), with flow 
rate at 1.2 mL/min. MS Conditions: APCI source in negative mode; vaporizer temperature, 450oC; 
corona discharge needle, 10 µA;  sheath and auxiliary gas pressures were 40 psi and 10 (arbitrary 
units), respectively.  SRM with transitions of 351.2→ 271.2 (PGD2/E2), 353.2→309.2 (PGF2α), 
303.3→259.3(AA) and 311.3→267.3 (AA-d8) were monitored. Other conditions were the same as 
described in Chapter Two. 
 
4. Sample Extraction and Derivatization. 
 Immediately after each microdialysate fraction was collected, 5 µL of the internal standard 
(AA-d8, 20 pg/µL) was added and the microdialysate was extracted twice with 150 µL of diethyl ether. 
The organic extracts were combined and dried with a SpeedVAc (Thermo Savant®, Holbrook, NY). 
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Then, 100 µL of PFB (in toluene solution) and 100 µL of DIPE (in toluene solution) were added to 
each vial and the resulting solution placed in a heating block at 60 oC for 1 h. The product was 
allowed to cool and then evaporated to dryness on a SpeedVac at room temperature. Reconstitution 
was performed by added 100 µL MeOH to each vial. The resulting solutions were then ready for 
HPLC-ECAPCI-MS/MS analysis. 
 
5. Selected Reaction Monitoring (SRM) Optimization.  
 SRM optimization was carried out in the same way as described in Chapter Four, except that 
1 ng/µL of individual standard solutions were injected. 
 
6. Calibration Curves  
The mixture standard solution (10 ng/µL) was further diluted with deoxygenated ethanol and 
calculated amounts were spiked into 1mL of deoxygenated aCSF containing HCl (0.1 mM final 
concentration) and BHT (0.025 µg/µL final concentration). Standard curves were prepared for each 
analyte of interest over the concentration range 0.2 pg/µL to 1 ng/µL (ca. 0.6 nM to 3.0 µM). The 
sample treatment for calibration standards was the same as for microdialysate samples, i.e., 105 µL 
standard mixture solution was spiked with 5 µL internal standard (AA-d8, 20pg / µL), extracted and 
derivatized the same way as previously described. The calibration curve was plotted using the ratio of 
analyte peak area to that of the internal standard, AA-d8. 
 
7. Animals and Surgical Procedures 
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Animals and surgical procedures were the same as in Chapter Four.  
 
8.   In Vivo Microdialysis Sample Collection. 
On the day of the experiment, the guide cannula was removed and replaced with a CMA 12® 
microdialysis probe with the tip 7.4 mm below dura. The probes were perfused with deoxygenated 
aCSF at 1.5 µL/min. Microdialysate was collected in a CMA 170® refrigerated fraction collector at 70 
min intervals. Each vial initially contained 1.0 M HCl (1/10 final volume of microdialysate) and 1.0 
µg/uL BHT (2.5% final volume) to insure eicosanoid stability. For each in vivo experiment a reagent 
blank was prepared. Thus, 105 µL aCSF was treated by the exact same procedure used with 
microdialysate samples. 
   
9.  Calculations and Statistics 
Data calculations and statistics was the same as described in Chapter Four. 
 
C. Results and Discussion 
1. CID Optimization for AA, PGE2, PGD2, and PGF2α. 
Daughter ion information and CID optimization were achieved by CID energy-step-increase 
experiments. The data processing technique for CID breakdown curve establishment was described in 
Chapter Four. 
Figures 7-2 to 7-9 present spectra and CID breakdown curves for all four analytes. The 
optimized SRM conditions are summarized in Table 7-1. 
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Figure 7- 3. MS/MS spectrum for AA 
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Figure 7- 4. CID breakdown curves for AA 
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Figure 7- 5. MS/MS spectrum for PGE2. 
 
 
 
Figure 7- 6. MS/MS spectrum for PGD2. 
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Figure 7- 7. CID breakdown curves for PGE2/PGD2 
 
 
 
Figure 7- 8. MS/MS spectrum for PGF2α. 
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Figure 7- 9. CID breakdown curve for PGF2α. 
 
 
Substance SRM optimized conditions 
AA 303 → 259 @ 18 eV 
PGE2 351 →271 @ 16 eV 
PGD2 351 →271 @ 16 eV 
PGF2α 353 →309 @ 23 eV 
Table 7- 1. SRM optimized conditions. 
 
PGE2, PGD2 are enantiomers and therefore are not distinguishable by MS analysis i.e., they 
both have the same parent ion and daughter ion patterns. However, they could be separated by normal 
phase HPLC chromatography utilized in this project. As shown in Figure 7-10. 
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Figure 7- 10. Chromatograms for PGE2/PGD2 standards. 
Figure 7-10 shows the results of three experiments: PGD2 standard, PGE2 standard , and 
PGE2/PGD2 mixture (both at the same concentration). For every experiment, reaction 351 →271 @ 16 
eV was monitored. The retention time for PGD2 was 3.15 min and for PGE2 was 3.45 min and, 
therefore, a baseline separation was achieved.  
2. Standard Curves and Sensitivity (Limits of Detection). 
 
Analyte Equation Correlation 
coefficient 
Liner range 
(nM) 
LOD 
(nM) 
AA y = −1.905 + 1.124 ⋅ X 0.9998 0.6−1500 0.1 
PGE2 y = −0.167 + 0.833 ⋅ X 0.9990 0.6−1500 0.1 
PGD2 y = −0.710 + 0.908 ⋅ X 0.9997 1.2−1500 0.5 
PGF2α y = −0.577 + 1.882 ⋅ X 0.9998 1.2−2000 0.2 
Table 7- 2. Calibration parameters, limit of detection (LOD) and linear dynamic range for all 
analytes 
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3. In Vivo Experiments.  
 
 
Figure 7- 11. Typical data of reagent blank, AA-d8 was internal standard. 
 
 
Figure 7- 12. Typical data from in vivo experiments: insertion of the microdialysis 
probe evoked a rise in extracellular (microdialysate) PGE2, PGD2, and PGF2α levels. 
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Figure 7- 13. Time-dependent effects of microdialysis probe insertion into rat striatum on 
microdialysate levels of PGE2. Data are mean ± SEM (n = 3). * p < 0.05. 
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Figure 7- 14. Time-dependent effects of microdialysis probe insertion into rat striatum on 
microdialysate levels of PGF2α. Data are mean ± SEM (n = 3). * p < 0.05. 
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 PGD2 was detected only in the first sample after probe insertion. The concentration of PGD2 
measured was 1.2 ± 0.3 nM (mean ± S.E.M., n=3). The insertion of the microdialysis probe caused 
PGF2α to significantly increase immediately. Subsequently, it slowly decreased to basal level in 2h. 
The probe insertion also caused PGE2 levels to increase. However, this increase was much slower than 
for PGF2α and required 4 h to reach the peak value of 3.5 nM PGE2. PGE2 then slowly declined to 
basal level (9-h). Interestingly, extracellular concentrations of PGE2 increased again showing a second 
peak value of 3 nM after approximately 15 h after which it declined slowly back to basal level 
It has previously been reported that insertion of the microdialysis probe evokes a rise in 
extracellular levels of ecosanoids.256,257 However, such studies did not employ HPLC-MS.  
 
D. Conclusions 
A highly sensitivity and specific HPLC-ECAPCI-MS/MS method has been developed and 
applied to the analysis of basal levels of several eicosanoids in rat striatal microdialystates. However, 
this analytical method was impaired by its low sample throughput and time-consuming sample 
preparation. Nonetheless, as an instrumental analysis technique, HPLC-ECAPCI-MS/MS proved to be 
capable of in vivo monitoring metabolites in very low abundance.    
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Chapter Eight 
 
Summary and Future Directions 
“If you cannot see it, it doesn’t exist!” − an unidentified scientist. 
This dissertation research was dedicated (except Chapter 7) in developing an automated 
HPLC-MS method to  monitor a number of important neurochemicals (metabolites) in rat brain 
striatum which might be of relevance to an understanding of the parthenogenesis of PD. Table 8-1 
summarizes all the compounds targeted in this dissertation research. 
 
Analyte LOD  Basal dialysate levels  
± SEM (n=3) 
Maximum dialysate levels*     
± SEM (n=3) 
DA 0.5 nM 6.4 ± 0.7 nM 1.4 ± 0.6 µM 
EPI 0.5 nM / / 
NE 1.0 nM 0.8 ±0.2 nM 13.3 ± 3.0 nM 
5-HT 0.5 nM 4.3 ± 2.1 nM 77.2 ± 22.5 nM 
3-MT 1.0 nM 3.5 ± 0.4 nM 217.0 ± 37.3 nM 
GSH 0.1 µM 0.6 ± 0.1 µM 3.7 ± 0.4 µM   
CySH 1.0 µM 6.2 ± 0.4 µM 67.2 ± 3.5 µM 
MPTP 1.0 nM  / 36.8 ± 5.0 µM 
MPP+ 0.5 nM / 482.4 ± 55.6 nM 
MPDP+ / / 76 ± 12** 
AA 0.1 nM / / 
PGE2 0.1 nM 0.7 ± 0.2 nM 3.5 ± 0.4 nM 
PGD2 0.5 nM / 1.2 ± 0.3 nM 
PGF2α 0.2 nM 2.0 ± 0.2 nM 12.0 ± 2.5 nM 
Table 8- 1. Targeted analytes and their detection limits.  
*The maximum level was caused by probe insertion for AA, PGE2, PGD2 and PGF2α; for other 
analytes it was caused by drug perfusion. **chromatograph peak area /106 
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In experiments, selected reactions monitoring (SRM) was applied to all analytes except MPTP, 
MPP+ MPDP+, where selected ion monitoring (SIM) was applied. AA, PGE2, PGD2 and PGF2α 
analysis were not performed by the fully automated system.  
Before employing MS-based techniques, routine detection techniques employed in this field 
were electrochemical or UV-vis, which were also the major analytical methods employed in our lab. 
For these techniques, people have to “guess” from the LC chromatography data − what did the 
chromatography peak represent? If it has a similar retention time to the standard, then…it might be the 
same compound. In HPLC-MS, MS and MS/MS spectra data enable us to “see” the analyte. If the data 
displays the same molecular mass, the same fragmentation pattern (daughter ions) and the same 
retention time as the standard, it most likely is the same compound as the standard. 
The fully automated system developed in the research and described in the dissertation is an 
essential tool for both method development and in vivo measurements.  
Thus, analyte calibration, SPE breakthrough curves, pre-column derivatization (if necessary), 
in vitro experiments (microdialysis probe recovery studies) and in vivo experiments were all carried 
out in a largely labor-free, precise, expeditious and fully automated way. Figure 8-1 describes all 
experiments required to fulfill a project. The green blocks in the graph represent the experimental 
procedures that can be approached by the fully automated system. 
Typically, all required experiments, including in vivo experiments employing multiple (n ≥ 3) 
animals would only take 2-3 weeks to accomplish.  
 
 146 
 
Figure 8- 1. General procedures for an in vivo project utilizing the fully automated system. 
 
The future directions of HPLC-MS techniques in PD studies is hard to predict for a number of 
reasons: 1) the application of HPLC-MS in this area has just started and still in its infancy; 2) 
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HPLC-MS technology is growing extremely rapidly; and, 3) The establishment of human metabolome, 
which doesn’t have a clear time schedule yet, could have profound impact on HPLC-MS applications 
in this field.  
Currently, the main obstacles for MS-based applications are the complexity and expense of 
mass spectrometers; the difficulties associated with their use; and the lower reliability of mass 
spectrometers compared to other analytical instruments, such as chromatographs. The next generation 
of mass spectrometers are focused on solving these problems.258-260 In addition, they will have 
unprecedented sensitivity, resolution and dynamic range − thanks for the exponential development of 
electronic technology and the urgent demand of life science.  
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